Windtree Therapeutics (WINT) 10-Q26 Nov 242024 Q3 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2024	Nov. 22, 2024
Document Information [Line Items]
Entity Central Index Key	0000946486
Entity Registrant Name	WINDTREE THERAPEUTICS INC /DE/
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-39290
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3171943
Entity Address, Address Line One	2600 Kelly Road, Suite 100
Entity Address, City or Town	Warrington
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18976-3622
City Area Code	215
Local Phone Number	488-9300
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	WINT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,989,828

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 2,300	$ 4,319
Prepaid expenses and other current assets	1,628	1,060
Total current assets	3,928	5,379
Property and equipment, net	128	183
Restricted cash	9	150
Operating lease right-of-use assets	1,133	1,444
Intangible assets	25,250	25,250
Total assets	30,448	32,406
Current Liabilities:
Accounts payable	2,054	809
Accrued expenses	1,650	1,618
Operating lease liabilities - current portion	468	436
Loans payable	444	233
Other current liabilities	525	900
Total current liabilities	14,426	3,996
Operating lease liabilities - non-current portion	784	1,161
Restructured debt liability - contingent milestone payments	0	15,000
Other liabilities	3,800	3,800
Deferred tax liabilities	4,887	5,058
Total liabilities	23,897	29,015
Mezzanine Equity:
Series C redeemable preferred stock, $0.001 par value; 18,820 and 0 shares authorized; 15,719 and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	2,142	0
Stockholders’ Equity:
Preferred stock, $0.001 par value; 4,975,680 and 5,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized; 2,340,429 and 333,145 shares issued at September 30, 2024 and December 31, 2023, respectively; 2,340,428 and 333,144 shares outstanding at September 30, 2024 and December 31, 2023, respectively	2	0
Additional paid-in capital	856,267	851,268
Accumulated deficit	(848,806)	(844,823)
Treasury stock (at cost); 1 share	(3,054)	(3,054)
Total stockholders’ equity	4,409	3,391
Total liabilities, mezzanine equity & stockholders’ equity	30,448	32,406
Series C Preferred Stock [Member]
Mezzanine Equity:
Series C redeemable preferred stock, $0.001 par value; 18,820 and 0 shares authorized; 15,719 and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	2,142	0
Series B Preferred Stock [Member]
Mezzanine Equity:
Series C redeemable preferred stock, $0.001 par value; 18,820 and 0 shares authorized; 15,719 and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	0	0
Embedded Derivative Financial Instruments, Convertible Promissory Note [Member]
Current Liabilities:
Derivative liability	347	0
Warrant Liability [Member]
Current Liabilities:
Derivative liability	8,621	0
June 2024 Commitment Note [Member]
Current Liabilities:
Convertible notes payable, current	$ 317	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	4,975,680	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	2,340,429	333,145
Common stock, shares outstanding (in shares)	2,340,428	333,144
Treasury stock, shares (in shares)	1	1
Series C Preferred Stock [Member]
Temporary equity, par value (in dollars per share)	$ 0.001	$ 0.001
Temporary equity, shares authorized (in shares)	18,820	0
Temporary equity, shares issued (in shares)	15,719	0
Temporary equity, shares outstanding (in shares)	15,719	0
Preferred stock, par value (in dollars per share)	$ 1,000
Series B Preferred Stock [Member]
Temporary equity, par value (in dollars per share)	$ 0.001	$ 0.001
Temporary equity, shares authorized (in shares)	5,500	0
Temporary equity, shares issued (in shares)	0	0
Temporary equity, shares outstanding (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Research and development	$ 1,968	$ 2,110	$ 14,084	$ 5,288
General and administrative	2,773	2,580	6,514	7,292
Loss on impairment of goodwill	0	0	0	3,058
Total operating expenses	4,741	4,690	20,598	15,638
Operating loss	(4,741)	(4,690)	(20,598)	(15,638)
Gain on debt extinguishment	71	0	14,591	0
Change in fair value of common stock warrant liability	2,166	0	2,166	0
Interest income	12	112	62	264
Interest expense	(51)	(13)	(174)	(38)
Other (expense) income, net	(446)	166	(530)	275
Total other income, net	1,752	265	16,115	501
Loss before income taxes	(2,989)	(4,425)	(4,483)	(15,137)
Income tax benefit (expense)	240	0	(71)	0
Net loss	(2,749)	(4,425)	(4,554)	(15,137)
Extinguishment of Series B Preferred Stock	572	0	572	0
Deemed dividend on Series C Preferred Stock	(1,573)	0	(1,573)	0
Net loss attributable to common stockholders	$ (3,750)	$ (4,425)	$ (5,555)	$ (15,137)
Net loss per share attributable to common stockholders
Basic and diluted (in dollars per share)	$ (4.23)	$ (15.47)	$ (8.64)	$ (80.95)
Weighted average number of common shares outstanding
Basic and diluted (in shares)	887	286	643	187

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Series B Preferred Stock, Mezzanine Equity [Member] ATM Program [Member]	Series B Preferred Stock, Mezzanine Equity [Member] ELOC Purchase Agreement [Member]	Series B Preferred Stock, Mezzanine Equity [Member]	Series C Preferred Stock Mezzanine Equity [Member] ATM Program [Member]	Series C Preferred Stock Mezzanine Equity [Member] ELOC Purchase Agreement [Member]	Series C Preferred Stock Mezzanine Equity [Member]	Common Stock [Member] ATM Program [Member]	Common Stock [Member] ELOC Purchase Agreement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member] ATM Program [Member]	Additional Paid-in Capital [Member] ELOC Purchase Agreement [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member] ATM Program [Member]	Retained Earnings [Member] ELOC Purchase Agreement [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member] ATM Program [Member]	Treasury Stock, Common [Member] ELOC Purchase Agreement [Member]	Treasury Stock, Common [Member]	Series A Preferred Stock, Mezzanine Equity [Member]	ATM Program [Member]	ELOC Purchase Agreement [Member]	Total
Balance (in shares) at Dec. 31, 2022									43,000									0	3,000
Balance at Dec. 31, 2022									$ 0			$ 837,598			$ (824,532)			$ (3,054)	$ 0			$ 10,012
Net loss									$ 0						(4,111)			$ 0	$ 0			(4,111)
Redemption of Series A Preferred Stock (in shares)									0									0	(3,000)
Exercise of common stock warrants, net of expenses of $276 (in shares)									7,000									0	0
Exercise of common stock warrants, net of expenses of $276									$ 0			843			0			$ 0	$ 0			843
Reverse split adjustments - fractional share round ups (in shares)									1,000									0	0
Stock-based compensation expense									$ 0			285			0			$ 0	$ 0			285
Balance (in shares) at Mar. 31, 2023									51,000									0	0
Balance at Mar. 31, 2023									$ 0			838,726			(828,643)			$ (3,054)	$ 0			7,029
Balance (in shares) at Dec. 31, 2022									43,000									0	3,000
Balance at Dec. 31, 2022									$ 0			837,598			(824,532)			$ (3,054)	$ 0			10,012
Net loss																						(15,137)
Balance (in shares) at Sep. 30, 2023									287,000									0	0
Balance at Sep. 30, 2023									$ 0			850,207			(839,669)			$ (3,054)	$ 0			7,484
Balance (in shares) at Mar. 31, 2023									51,000									0	0
Balance at Mar. 31, 2023									$ 0			838,726			(828,643)			$ (3,054)	$ 0			7,029
Net loss									0			0			(6,601)			0	0			(6,601)
Stock-based compensation expense									$ 0			382			0			$ 0	$ 0			382
Issuance of stock (in shares)									236,000									0	0
Issuance of stock									$ 0			10,794			0			$ 0	$ 0			10,794
Balance (in shares) at Jun. 30, 2023									287,000									0	0
Balance at Jun. 30, 2023									$ 0			849,902			(835,244)			$ (3,054)	$ 0			11,604
Net loss									0			0			(4,425)			0	0			(4,425)
Stock-based compensation expense									$ 0			305			0			$ 0	$ 0			305
Balance (in shares) at Sep. 30, 2023									287,000									0	0
Balance at Sep. 30, 2023									$ 0			850,207			(839,669)			$ (3,054)	$ 0			7,484
Balance (in shares) at Dec. 31, 2023			0			0			333,000									0
Balance at Dec. 31, 2023			$ 0			$ 0			$ 0			851,268			(844,823)			$ (3,054)				3,391
Net loss			0			0			0			0			10,219			0				10,219
Stock-based compensation expense			$ 0			$ 0			$ 0			164			0			$ 0				164
Issuance of stock (in shares)	0			0			143,000									0
Issuance of stock	$ 0			$ 0			$ 1			$ 1,366			$ 0			$ 0				$ 1,367
Issuance of common stock, equity consideration in debt extinguishment (in shares)			0			0			34,000									0
Issuance of common stock, equity consideration in debt extinguishment			$ 0			$ 0			$ 0			280			0			$ 0				280
Balance (in shares) at Mar. 31, 2024			0			0			510,000									0
Balance at Mar. 31, 2024			$ 0			$ 0			$ 1			853,078			(834,604)			$ (3,054)				15,421
Balance (in shares) at Dec. 31, 2023			0			0			333,000									0
Balance at Dec. 31, 2023			$ 0			$ 0			$ 0			851,268			(844,823)			$ (3,054)				3,391
Net loss																						$ (4,554)
Reverse split adjustments - fractional share round ups (in shares)																						106
Issuance of stock (in shares)																				143,120
Balance (in shares) at Sep. 30, 2024			0			16,000			2,340,000									0
Balance at Sep. 30, 2024			$ 0			$ 2,142			$ 2			856,267			(848,806)			$ (3,054)				$ 4,409
Balance (in shares) at Mar. 31, 2024			0			0			510,000									0
Balance at Mar. 31, 2024			$ 0			$ 0			$ 1			853,078			(834,604)			$ (3,054)				15,421
Net loss			$ 0			$ 0			$ 0			0			(12,024)			$ 0				(12,024)
Reverse split adjustments - fractional share round ups (in shares)			0			0			82,000									0
Stock-based compensation expense			$ 0			$ 0			$ 0			97			0			$ 0				97
Issuance of stock (in shares)			6,000			0			0									0
Issuance of stock			$ 6,954			$ 0			$ 0			0			0			$ 0				0
Balance (in shares) at Jun. 30, 2024			6,000			0			592,000									0
Balance at Jun. 30, 2024			$ 6,954			$ 0			$ 1			853,175			(846,628)			$ (3,054)				3,494
Net loss			0			0			0			0			(2,750)			0				(2,749)
Stock-based compensation expense			$ 0			$ 0			$ 0			86			0			$ 0				86
Issuance of stock (in shares)		0	0		0	6,000		1,435,000	0								0	0			1,400,000
Issuance of stock		$ 0	$ 0		$ 0	$ 557		$ 1	$ 0		$ 4,370	0		$ 0	0		$ 0	$ 0			$ 4,371	0
Issuance of common stock, equity consideration in debt extinguishment (in shares)			(6,000)			3,000			0									0
Issuance of common stock, equity consideration in debt extinguishment						$ 344			$ 0			0			0			$ 0				0
Exchange of Series B preferred stock			$ (6,954)			$ 992			$ 0			0			572			$ 0				572
Issuance of Series C preferred stock as consideration for services (in shares)			0			0			0									0
Issuance of Series C preferred stock as consideration for services			$ 0			$ 24			$ 0			0			0			$ 0				0
Conversions of Series C preferred stock (in shares)			0			(1,000)			313,000									0
Conversions of Series C preferred stock			$ 0			$ (154)			$ 0			209			0			$ 0				209
Redemptions of Series C preferred stock (in shares)			0			(1,000)			0									0
Redemptions of Series C preferred stock			$ 0			$ (74)			$ 0			(772)			0			$ 0				(772)
Deemed dividends on Series C preferred stock			0			454			0			(454)			0			0				(454)
Deemed cash dividends on Series C preferred stock			$ 0			$ 0			$ 0						0			$ 0				(347)
Deemed cash dividends on Series C preferred stock												(347)
Balance (in shares) at Sep. 30, 2024			0			16,000			2,340,000									0
Balance at Sep. 30, 2024			$ 0			$ 2,142			$ 2			$ 856,267			$ (848,806)			$ (3,054)				$ 4,409

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023
ATM Program [Member]
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs			$ 44
ELOC Purchase Agreement [Member]
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 156
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs, Exercise of Warrants Cost					$ 276
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 172	$ 68		$ 1,630

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (4,554,000)	$ (15,137,000)
Adjustments to reconcile net loss to net cash used in operating activities:
In-process research and development expenses in connection with the Varian asset acquisition	7,419,000	0
Depreciation and amortization	66,000	60,000
Amortization of right-of-use assets	311,000	309,000
Amortization of debt discount and debt issuance costs	86,000	0
Stock-based compensation	434,000	972,000
Non-cash expense related to equity consideration for services	189,000	0
Loss on ELOC commitment note and derivative liability	590,000	0
Loss on impairment of goodwill	0	3,058,000
Loss on sale and disposal of property and equipment	0	12,000
Gain on debt extinguishment	(14,591,000)	0
Unrealized gain on foreign exchange rate changes	(180,000)	(261,000)
Change in fair value of common stock warrant liability	(2,166,000)	0
Change in fair value of derivative liabilities	(33,000)	0
Change in fair value of senior secured notes	150,000	0
Changes in assets and liabilities:
Prepaid expenses and other current assets	(11,000)	443,000
Accounts payable	1,245,000	695,000
Accrued expenses	48,000	317,000
Operating lease liabilities	(345,000)	(338,000)
Other current liabilities	(375,000)	0
Net cash used in operating activities	(11,717,000)	(9,870,000)
Cash flows from investing activities:
Purchase of property and equipment	(12,000)	(15,000)
Net cash used in investing activities	(12,000)	(15,000)
Cash flows from financing activities:
Proceeds from private placements, net of issuance costs	3,925,000	0
Redemptions of Series C Preferred Stock	(847,000)	0
Cash dividends on Series C Preferred Stock	(347,000)	0
Proceeds from issuance of common stock and warrants, net of issuance costs	0	10,794,000
Proceeds from ATM Program, net of issuance costs	1,367,000	0
Proceeds from senior convertible notes payable, net of issuance costs	1,312,000	0
Principal payments on senior convertible notes payable	(150,000)	0
Proceeds from senior secured and unsecured notes, net of issuance costs	550,000	0
Principal payments on loans payable	(344,000)	(563,000)
Payments on debt extinguishment	(200,000)	0
Proceeds from exercise of common stock warrants, net of expenses	0	843,000
Net cash provided by financing activities	9,569,000	11,074,000
Net (decrease) increase in cash, cash equivalents, and restricted cash	(2,160,000)	1,189,000
Cash, cash equivalents, and restricted cash - beginning of period	4,469,000	6,326,000
Cash, cash equivalents, and restricted cash - end of period	2,309,000	7,515,000
Supplementary disclosure of non-cash activity:
Fair value upon issuance of common stock warrant liability	10,787,000	0
Fair value of common stock consideration related to debt extinguishment	280,000	0
Prepayment of insurance through third-party financing	555,000	778,000
January 2023 Existing Warrants [Member]
Supplementary disclosure of non-cash activity:
Fair value of warrant modifications related to the warrant exercise inducement	0	1,238,000
February 2023 Existing Warrants [Member]
Supplementary disclosure of non-cash activity:
Fair value of warrant modifications related to the warrant exercise inducement	0	274,000
Senior Convertible Notes [Member]
Supplementary disclosure of non-cash activity:
Fair value upon issuance of derivative liability	458,000	0
Embedded Derivative Financial Instruments, Convertible Promissory Note [Member]
Supplementary disclosure of non-cash activity:
Fair value upon issuance of derivative liability	284,000	0
Varian Asset Acquisition [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
In-process research and development expenses in connection with the Varian asset acquisition	7,500,000
Series B Preferred Stock [Member]
Cash flows from financing activities:
Issuance costs related to Series B Preferred Stock	(68,000)	0
Series B Preferred Stock [Member] \| Varian Asset Acquisition [Member]
Supplementary disclosure of non-cash activity:
Fair value of Series B Preferred Stock issued in connection with the Varian asset acquisition	7,022,000	0
Series C Preferred Stock [Member]
Supplementary disclosure of non-cash activity:
Non-cash issuance costs allocated to Series C preferred stock	37,000
ELOC Purchase Agreement [Member]
Cash flows from financing activities:
Proceeds from equity issuances, net	4,371,000	0
Private Placement [Member]
Supplementary disclosure of non-cash activity:
Private placement proceeds allocated to common stock warrant liability	$ 3,331,000	$ 0

Note 1 - The Company and Descri

Note 1 - The Company and Description of Business	9 Months Ended
Note 1 - The Company and Description of Business	Sep. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 – The Company and Description of Business We are a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Our portfolio of product candidates includes istaroxime, a Phase 2 candidate that inhibits the sodium-potassium ATPase and also activates sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, for acute heart failure and/or associated cardiogenic shock; preclinical SERCA2a activators for heart failure; rostafuroxin for the treatment of hypertension in patients with a specific genetic profile; and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor (topical and oral formulations), being developed for potential application in rare and broad oncology indications. We also have a licensing business model with partnership out-licenses currently in place. Our lead product candidate, istaroxime, is a first-in-class, dual-acting agent being developed to increase blood pressure and improve cardiac function in patients with cardiogenic shock and to improve cardiac function in patients with acute heart failure, or AHF, and reverse the hypotension and hypoperfusion associated with heart failure that deteriorates to cardiogenic shock. Istaroxime demonstrated significant improvement in both systolic and diastolic aspects of cardiac function and was generally well tolerated in four Phase 2 clinical trials. Istaroxime has been granted Fast Track designation for the treatment of AHF by the U.S. Food and Drug Administration, or FDA. Based on the profile observed in our Phase 2 clinical studies in AHF, where istaroxime significantly improved cardiac function and systolic blood pressure, or SBP, in acute decompensated heart failure patients and had a favorable renal profile, we initiated a Phase 2 global clinical study, or the SEISMiC Study, to evaluate istaroxime for the treatment of early cardiogenic shock (Society for Cardiovascular Angiography and Interventions, or SCAI, Stage B shock), a severe form of AHF characterized by very low blood pressure and risk for hypoperfusion to critical organs and mortality. In April 2022, we announced our observations in the SEISMiC Study that istaroxime rapidly and significantly increased SBP while also improving cardiac function and preserving renal function. We believe that istaroxime has the potential to fulfill an unmet need in early and potentially more severe cardiogenic shock. We further believe that the data from the SEISMiC Study supports continued development in both cardiogenic shock and AHF. In September 2024, we announced positive topline results from our Phase 2b SEISMiC Extension Study, or the SEISMiC Extension, which demonstrated that istaroxime infused intravenously significantly improves cardiac function and blood pressure without increasing heart rate or clinically significant cardiac rhythm disturbances. Additionally, we have initiated a study in more severe SCAI Stage C cardiogenic shock, or the SEISMiC C Study, to evaluate the safety and efficacy of istaroxime in cardiogenic shock patients who are also receiving standard of care rescue therapy for shock. The SEISMiC C Study is expected to enroll up to 100 subjects with SCAI Stage C cardiogenic shock with enrollment anticipated to be completed in late 2025. An unblinded review of the data from the first 20 subjects is planned to take place in early Q2 2025. Our ability to complete this study with its intended sample size is dependent upon our ability to secure adequate resourcing for the program through financing efforts or business development activities. Our heart failure cardiovascular portfolio also includes other SERCA2a activators. One family of compounds has the dual mechanism of action that includes inhibition of the sodium-potassium ATPase as well as activation of SERCA2a. The other family of compounds are considered selective SERCA2a activators and are devoid of activity against the sodium-potassium ATPase. This research program is evaluating these preclinical product candidates, including oral and intravenous SERCA2a activator heart failure compounds. These candidates would potentially be developed for both acute decompensated and chronic out-patient heart failure. In addition, our cardiovascular drug product candidates include rostafuroxin, a novel product candidate for the treatment of hypertension in patients with a specific genetic profile. We are pursuing potential licensing arrangements and/or other strategic partnerships and do not intend to advance the development of rostafuroxin without securing such an arrangement or partnership. Our cardiovascular assets and programs are associated with a regional licensed partnership with Lee’s Pharmaceutical (HK) Ltd., or Lee’s (HK), for the development and commercialization of our product candidate, istaroxime, in Greater China. In addition to istaroxime, the agreement also licenses our preclinical next-generation dual mechanism SERCA2a activators, and rostafuroxin. In addition, we are supporting the efforts of Lee’s (HK) in starting a Phase 3 trial in AHF with istaroxime. On April 2, 2024, we entered into an Asset Purchase Agreement, or the Asset Purchase Agreement, with Varian Biopharmaceuticals, Inc., or Varian. Pursuant to the Asset Purchase Agreement, we purchased all of the assets of Varian’s business associated with a license agreement, dated as of July 5, 2019, by and between Varian and Cancer Research Technology Limited, or the Licence Agreement, which includes the Licence Agreement, all rights in molecules and compounds subject to the Licence Agreement, know-how and inventory of drug substance, or the Transferred Assets. The Transferred Assets include a novel, potential high-potency, specific, aPKCi inhibitor with possible broad use in oncology as well as certain rare malignant diseases. The asset platform includes two formulations (topical and oral) of an aPKCi inhibitor. We plan to advance investigational new drug enabling activities and are in the process of determining the expected clinical development plan for the platform. Our ability to advance our development programs is dependent upon our ability to secure additional capital in both the near and long-term, through public or private securities offerings; convertible debt financings; and/or potential strategic opportunities, including licensing agreements, drug product development, marketing collaboration arrangements, pharmaceutical research cooperation arrangements, and/or other similar transactions in geographic markets, including the U.S., and/or through potential grants and other funding commitments from U.S. government agencies, in each case, if available. We have engaged with potential counterparties in various markets and will continue to pursue non-dilutive sources of capital as well as potential private and public securities offerings. There can be no assurance, however, that we will be able to identify and enter into public or private securities offerings on acceptable terms and in amounts sufficient to meet our needs or qualify for non-dilutive funding opportunities under any grant programs sponsored by U.S. government agencies, private foundations, and/or leading academic institutions, or identify and enter into any strategic transactions that will provide the additional capital that we will require. If none of these alternatives is available, or if available and we are unable to raise sufficient capital through such transactions, we potentially could be forced to limit or cease our development activities, as well as modify or cease our operations, either of which would have a material adverse effect on our business, financial condition, and results of operations. The reader is referred to, and encouraged to read in its entirety, “Item 1 – Business” in our Annual Report on Form 10-K for the year ended that we filed with the Securities and Exchange Commission, or the SEC, on , which contains a discussion of our business and business plans, as well as information concerning our proprietary technologies and our current and planned development programs.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	9 Months Ended
Note 2 - Basis of Presentation	Sep. 30, 2024
Notes to Financial Statements
Basis of Accounting [Text Block]	Note 2 – Basis of Presentation The interim unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S., or US GAAP, for interim financial information in accordance with the instructions to Form 10-Q and include accounts of Windtree Therapeutics, Inc. and its wholly owned subsidiaries. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete consolidated financial statements. Intercompany balances and transactions have been eliminated in consolidation. All adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. Operating results for the are not necessarily indicative of the results that may be expected for the year ending . The consolidated balance sheet at has been derived from the Company’s audited consolidated financial statements. There have been no changes to our significant accounting policies since . The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with our annual audited consolidated financial statements and related notes as of and for the year ended contained in our Annual Report on Form 10-K for the year ended . The accompanying condensed consolidated financial statements reflect the 1-for-18 reverse split of our common stock that was approved by our Board of Directors and stockholders and made effective on April 19, 2024. All share and per share information herein that relates to our common stock prior to the effective date has been retroactively restated to reflect the reverse stock split.

Note 3 - Going Concern and Mana

Note 3 - Going Concern and Management's Plans	9 Months Ended
Note 3 - Going Concern and Management's Plans	Sep. 30, 2024
Notes to Financial Statements
Liquidity Disclosures [Text Block]	Note 3 – Going Concern and Management’s Plans We are subject to risks common to companies in the biotechnology industry, including but not limited to the need for additional capital, risks of failure of preclinical and clinical studies, the need to obtain marketing approval and reimbursement for any drug product candidate that we may identify and develop, the need to successfully commercialize and gain market acceptance of our product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, and risks associated with our international operations in Taiwan and activities abroad, including but not limited to having foreign suppliers, manufacturers, and clinical sites in support of our development activities. We have incurred net losses since inception. Our net loss was $2.7 million and $4.6 million, respectively, for the three and nine months ended . Included in our net loss for the three and nine months ended September 30, 2024 is $2.2 million related to the change in fair value of our common stock warrant liability. Also included in our net loss for the nine months ended September 30, 2024 is $7.5 million of non-cash R&D expense related to costs in connection with the Varian asset acquisition and a $14.6 million gain on debt extinguishment. For the , our net loss was million and $15.1 million, respectively. Included in our net loss for the is a $3.1 million loss on impairment of goodwill (See the section titled, “ ”). We expect to continue to incur operating losses for at least the next several years. As of , we had an accumulated deficit of million. Our future success is dependent on our ability to fund and develop our product candidates, and ultimately upon our ability to attain profitable operations. We have devoted substantially all of our financial resources and efforts to research and development expense and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital, and accordingly, our ability to execute our future operating plans. In June 2024, we entered into a Common Stock Purchase Agreement, or the ELOC Purchase Agreement, establishing an equity line of credit with the purchaser, or the Purchaser, whereby we have the right, but not the obligation, to sell to the Purchaser, and the Purchaser is obligated to purchase, up to $35 million of newly issued shares of our common stock. For the three months ended September 30, 2024, we sold 1.4 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $3.1 million following mandatory redemption payments on our Series C Preferred Stock (See the section titled, “Note 13 - Mezzanine Equity and Stockholders' Equity - Common Stock Purchase Agreement” for further details). In addition, in July 2024, we completed two private placement transactions for aggregate gross proceeds of approximately $13.9 million, which consists of approximately $4.4 million of new funding and a $9.5 million payment through the full cancellation and extinguishment of certain holders outstanding senior notes, including secured notes, and shares of our Series B Convertible Preferred Stock. Net proceeds related to these private placements was $2.3 million (See the section titled, “Note 13 - Mezzanine Equity and Stockholders' Equity - First Private Placement and Second Private Placements” for further details). As of , we had cash and cash equivalents of million and current liabilities of million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the additional redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. We do not have sufficient cash and cash equivalents as of the date of this Quarterly Report on Form 10-Q to support our operations for at least the 12 months following the date that the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern. To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans to secure additional capital, potentially through a combination of public or private securities offerings, convertible debt financings, and/or strategic transactions, including potential licensing arrangements, alliances, and drug product collaborations focused on specified geographic markets; however, none of these alternatives are committed at this time. There can be no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all, or identify and enter into any strategic transactions that will provide the capital that we will require. If we fail to raise sufficient capital, we potentially could be forced to limit or cease our development activities, as well as modify or cease our operations, either of which would have a material adverse effect on our business, financial condition, and results of operations. Accordingly, management has concluded that substantial doubt exists with respect to our ability to continue as a going concern for at least 12 months after the issuance of the accompanying financial statements. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Note 4 - Summary of Significant

Note 4 - Summary of Significant Accounting Policies	9 Months Ended
Note 4 - Summary of Significant Accounting Policies	Sep. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 4 – Summary of Significant Accounting Policies Principles of Consolidation The interim unaudited condensed consolidated financial statements are prepared in accordance with US GAAP and include accounts of Windtree Therapeutics, Inc. and its wholly owned subsidiaries, CVie Investments Limited and its wholly owned subsidiary, CVie Therapeutics Limited; and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.). Intangible Assets and Goodwill We record acquired intangible assets and goodwill based on estimated fair value. The identifiable intangible assets resulting from the CVie Therapeutics acquisition in December 2018 relate to in-process research and development, or IPR&D, of istaroxime and rostafuroxin. The IPR&D assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may be impaired. During the , no events or changes in circumstances occurred indicating that our IPR&D intangible assets were more likely than not impaired. Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination and is not amortized. It is reviewed for impairment at least annually or when events or changes in the business environment indicate that its carrying value may be impaired. During each of the first and second quarters of 2023, the continued declining trend in the closing share price of our common stock suggested that the fair value of our reporting unit was more likely than not less than its carrying value. Based on interim goodwill impairment tests, we determined that the fair value of our reporting unit was more likely than not less than its carrying value. As a result, we recorded a loss on impairment of goodwill of $0.5 million in the first quarter of 2023 and an additional loss of $2.6 million, representing the remaining balance of goodwill, in the second quarter of 2023. For the nine months ended September 30, 2023, the aggregate loss on impairment of goodwill is $3.1 million, recognized within operating expenses in our condensed consolidated statements of operations. As of June 30, 2023, goodwill was written down to zero and , goodwill was zero The following table represents identifiable intangible assets as of and : September 30, December 31, (in thousands) 2024 2023 Istaroxime drug candidate $ 22,340 $ 22,340 Rostafuroxin drug candidate 2,910 2,910 Intangible assets 25,250 25,250 Acquired In-Process Research and Development Expenses Acquired IPR&D expenses include consideration for the purchase of IPR&D through asset acquisitions and license agreements as well as payments made in connection with asset acquisitions and license agreements upon the achievement of development milestones. We evaluate in-licensed agreements for IPR&D projects to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the in-licensed agreement for IPR&D does not meet the definition of a business and the assets have not reached technological feasibility and have no alternative future use, we expense payments made under such license agreements as research and development expense in the consolidated statements of operations. In those cases, payments for milestones achieved and payments for a product license prior to regulatory approval of the product are expensed in the period incurred. Payments made in connection with regulatory and sales-based milestones are capitalized and amortized to cost of revenue. Convertible Debt and Equity Instruments We review the terms of convertible debt and equity instruments to determine whether there are conversion features or embedded derivative instruments including embedded conversion options that are required to be bifurcated and accounted for separately as derivative financial instruments under ASC Topic 815, Derivatives and Hedging In circumstances where the convertible instrument contains more than one embedded derivative instrument, including conversion options that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single compound instrument. Also, in connection with the sale of convertible debt and equity instruments, we may issue free standing warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. When convertible debt or equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for separately, the total proceeds allocated to the convertible host instruments are first allocated to the fair value of the bifurcated derivative instrument. The remaining proceeds, if any, are then allocated to the convertible instruments themselves, usually resulting in those instruments being recorded at a discount from their face amount. When we issue debt securities, which bear interest at rates that are lower than market rates, we recognize a discount, which is offset against the carrying value of the debt. Such discount from the face value of the debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to income. Derivative Financial Instruments Derivatives are recorded on the consolidated balance sheet at fair value. The conversion features of the convertible notes are embedded derivatives and are separately valued and accounted for on the consolidated balance sheet with changes in fair value recognized during the period of change as a separate component of other income (expense). Fair values for exchange-traded securities and derivatives are based on quoted market prices. The pricing model we use for determining the fair value of non-exchange traded derivatives is the Monte Carlo Model. Valuations derived from this model are subject to ongoing internal and external verification and review. The model uses market-sourced inputs such as interest rates and stock price volatilities. Foreign Currency Transactions The functional currency for our foreign subsidiary is U.S. Dollars. We remeasure monetary assets and liabilities that are not denominated in the functional currency at exchange rates in effect at the end of each period. Gains and losses from the remeasurement of foreign currency transactions are recognized in other (expense) income, net. Foreign currency transactions resulted in a net of approximately million and a net gain of million for the three-month periods ended , respectively. Foreign currency transactions resulted in net of approximately million and million for the -month periods ended , respectively. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including intangible assets and goodwill, at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents are held at domestic and foreign financial institutions and consist of liquid investments and money market funds that are readily convertible into cash. Concentration of Credit Risk Financial instruments, which potentially subject us to credit risk, consist principally of cash and cash equivalents. All cash and cash equivalents are held in U.S. financial institutions and money market funds. At times, we may maintain cash balances in excess of the federally insured amount of $250,000 per depositor, per insured bank, for each account ownership category. Although we currently believe that the financial institutions with whom we do business will be able to fulfill their commitments to us, there is no assurance that those institutions will be able to continue to do so. We have not experienced any credit losses associated with our balances in such accounts. Severance In July 2023, we entered into a separation agreement with an executive, which provided that the former employee would be entitled to receive (i) a severance amount equal to the sum of the employee’s base salary then in effect and (ii) subject to certain exceptions, a pro rata bonus commensurate with the bonus awarded to other contract executives for 2023, prorated for the number of days of the employee’s employment during 2023, and payable at the time that other contract executives are paid bonuses with respect to 2023. The severance amount related to the departure of this executive was approximately $0.5 million, which was accrued in general and administrative expense at the date of the separation, and was paid ratably through July 2024. In June 2023, we implemented certain reductions in headcount. The total severance cost for impacted employees was approximately $0.2 million, which was accrued in research and development expense at the date of the separations and was paid ratably through December 2023. Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three ten Restructured Debt Liability – Contingent Milestone Payment In conjunction with the November 2017 restructuring and retirement of long-term debt, we established a $15.0 million long-term liability for contingent milestone payments potentially due under the Exchange and Termination Agreement dated as of October 27, 2017, or the Milestone Agreement, between ourselves and affiliates of Deerfield Management Company L.P., or Deerfield. The liability was recorded at the full value of the contingent milestones and was to be carried at full value until the milestones were achieved and paid or the milestones were not achieved and the liability was written off as a gain on debt extinguishment. On January 24, 2024, we and Deerfield entered into an Exchange and Termination Agreement, or the Exchange and Termination Agreement, wherein Deerfield agreed to terminate its rights to receive certain milestone payments in exchange for (i) cash in the aggregate amount of $0.2 million and (ii) an aggregate of 33,793 shares of our common stock, par value $0.001 per share (See the section titled, “Note 12 - Restructured Debt Liability”). Research and Development We account for research and development expense by the following categories: (a) direct clinical and preclinical development programs, (b) product development and manufacturing, and (c) clinical, medical, and regulatory operations. Research and development expense includes personnel, facilities, manufacturing and quality, pharmaceutical development, research, clinical, regulatory, and other preclinical and clinical activities. Research and development costs are charged to operations as incurred in accordance with Accounting Standards Codification, or ASC, Topic 730, Research and Development Income Taxes We account for income taxes in accordance with ASC Topic 740, Accounting for Income Taxes We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset as there can be no assurance of realization. Net Loss per Share Attributable to Common Stockholders Net loss is adjusted for any deemed dividends to preferred stockholders to compute net loss attributable to common stockholders. Net loss is also adjusted for any impact to retained earnings related to the extinguishment of equity securities. The Series C preferred stock and the ELOC commitment note payable are participating securities. Accordingly, in any period in which we report net income attributable to common stockholders, basic earnings per share is computed using the “two-class” method. Under this method, net income is reduced by any dividends earned and the remaining earnings (undistributed earnings) are allocated to common stock and each series of participating securities to the extent that each participating security may share in earnings as if all of the earnings for the period had been distributed. The total earnings allocated to common stock is then divided by the number of outstanding shares to which the earnings are allocated to determine the earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the participating securities have no obligation to fund losses. Diluted net income per common share is computed under the two-class method by using the weighted-average number of shares of common stock outstanding, plus the effect of any other potentially dilutive securities outstanding for the period. In addition, the Company analyzes the potential dilutive effect of the outstanding participating securities under the “if-converted” method when calculating diluted earnings per share, in which it assumes that the outstanding participating securities convert into common stock at the beginning of the period, or when issued if later. The Company reports the more dilutive of the approaches (two class or “if-converted”) as their diluted net income per share during the period. For periods in which a net loss exists, basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by giving effect to all potentially dilutive securities outstanding for the period. As of , the number of shares of common stock potentially issuable upon the exercise of certain stock options and warrants, the vesting of restricted stock units, and the conversion of Series C preferred stock and the ELOC commitment note payable was million and 0.3 million shares, respectively. For the three and nine months ended , all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted weighted-average shares of common stock outstanding. We do not have any components of other comprehensive (loss) income.

Note 5 - Fair Value Measurement

Note 5 - Fair Value Measurements	9 Months Ended
Note 5 - Fair Value Measurements	Sep. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 5 – Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows: ● Level 1 – Quoted prices in active markets for identical assets and liabilities. ● Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Fair Value on a Recurring Basis The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented: Fair Value Fair value measurement using September 30, (in thousands) 2024 Level 1 Level 2 Level 3 Assets: Money market funds $ 592 $ 592 $ - $ - Total Assets $ 592 $ 592 $ - $ - Liabilities: Common stock warrant liability $ (8,621 ) $ - $ - $ (8,621 ) Derivative liability - ELOC commitment note (347 ) - - (347 ) Total Liabilities $ (8,968 ) $ - $ - $ (8,968 ) Fair Value Fair value measurement using December 31, (in thousands) 2023 Level 1 Level 2 Level 3 Assets: Money market funds $ 3,532 $ 3,532 $ - $ - Total Assets $ 3,532 $ 3,532 $ - $ - The money market funds were classified as cash and cash equivalents on the consolidated balance sheets and were within Level 1 of the fair value hierarchy. The aggregate fair value of the Company’s money market funds approximated amortized cost. The fair value of the common stock warrant liability is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. The following table provides a summary of the change in the estimated fair value of the common stock warrant liability: Three and Nine Months Ended September 30, 2024 Issuance of common stock warrants $ 10,787 Change in fair value (2,166 ) Balance at September 30, 2024 $ 8,621 In determining the initial fair value of the common stock warrants at their respective issuance dates, we used a Black Scholes pricing model. For the subsequent measurement at September 30, 2024, we used a Monte Carlo simulation. The following table provides a summary of the significant inputs used in these valuations: July 22, 2024 Issuance Date July 29, 2024 Issuance Date September 30, 2024 Fair value of underlying equity $ 3.56 $ 3.29 $ 2.39 Exercise price $ 4.11 $ 4.11 $ 4.11 Volatility 108.4 % 115.6 % n/a Risk-free interest rate 4.2 % 4.1 % 3.6 Expected term (in years) 5.5 5.5 5.3 Discounting factor n/a n/a 0.83 The fair value of the derivative liability-ELOC commitment note is also based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. The following table provides a summary of the change in the estimated fair value of the derivative liability: Three and Nine Months Ended September 30, 2024 Initial recognition of derivative liability $ 286 Change in fair value 61 Balance at September 30, 2024 $ 347 In determining the initial fair value of the derivative liability and for the subsequent measurement at September 30, 2024, we used a Monte Carlo simulation. The following table provides a summary of the significant inputs used in these valuations: June 26, 2024 Issuance Date September 30, 2024 Fair value of underlying equity $ 3.22 2.3442.3939 Volatility 87.3%-91.7 % 190.8%-194.4 % Risk-free interest rate 5.1 % 4.2 % Conversion price discount 20.0 % 20.0 % Discounting period (in years) 1.0 0.7 Discount rate 20.2 % 12.5 % Discounting factor 0.83 0.92 Fair Value on a Non-Recurring Basis Certain of our assets were measured at fair value on a non-recurring basis during the and the year ended . Our goodwill was recorded at its estimated fair value as a result of the impairment tests performed in 2023, which resulted in the goodwill being written down to zero – Intangible Assets and Goodwill”). In order to perform the goodwill impairment test, we compared the estimated fair value of our reporting unit to its carrying value. Significant factors considered in estimating the fair value of our reporting unit included the use of the quoted market price and related market capitalization of our common stock, adjusted for an estimated control premium based on transactions completed by comparable companies. Quantitative information about the significant unobservable inputs used in the fair value measurement of the reporting unit included an estimated control premium of 50% for both periods.

Note 6 - Senior Convertible Not

Note 6 - Senior Convertible Notes Payable	9 Months Ended
Note 6 - Senior Convertible Notes Payable	Sep. 30, 2024
Notes to Financial Statements
Convertible Note Payable Disclosure [Text Block]	Note 6 – Senior Convertible Notes Payable On April 2, 2024, we entered into the April Purchase Agreement pursuant to which we agreed to sell the Senior Convertible Notes for $1.35 million of net proceeds. The Senior Convertible Notes were convertible into shares of our common stock at an initial conversion price of $6.4854, which was subject to adjustment upon the occurrence of specified events to no lower than $1.2978, subject to any stock split, stock dividend, stock combination, recapitalization or other similar transaction involving our common stock. The Senior Convertible Notes were senior obligations and accrued interest at a rate of 10.0% per annum, payable in arrears on the first calendar day of each calendar month, beginning on May 2, 2024, unless an event of default had occurred, upon which interest would accrue at 18.0% per annum. The Senior Convertible Notes had a maturity date of January 2, 2025 unless earlier converted or redeemed (upon the satisfaction of certain conditions). The Senior Convertible Notes contained certain conversion and redemption features requiring bifurcation as separate derivative liabilities. We initially recorded the fair value of the embedded features in the amount of $0.5 million as a derivative liability in our condensed consolidated balance sheet. The derivative was adjusted to fair value at each reporting period, with the change in the fair value recorded in change in fair value of derivatives that is a component of other income (expense) in our condensed consolidated statement of operations. For the three and nine months ended September 30, 2024, the change in fair value of the derivative was $0.1 million and $0.4 million, respectively, and was recorded in other expense. In connection with the issuance of the Senior Convertible Notes, we incurred $38,000 in debt issuance costs. The associated debt issuance costs were capitalized and were presented as an offset to the Senior Convertible Notes and, along with the debt discount of $161,000 associated with the bifurcated derivative, were amortized as additional interest expense over the term of the Senior Convertible Notes at an effective interest rate of 30.32%. For the three and nine months ended September 30, 2024, the interest expense was $0.2 million. We used the proceeds from our First PIPE to extinguish the Senior Convertible Notes and we wrote-off the remaining related derivative liability of $0.4 million and recognized a gain on debt extinguishment of $0.1 million. Refer to Note 13, “Mezzanine Equity and Stockholders' Equity - Accounting for the First and Second Private Placements ” for additional details. As of September 30, 2024, there are no Senior Convertible Notes outstanding.

Note 7 - ELOC Commitment Note P

Note 7 - ELOC Commitment Note Payable	9 Months Ended
Note 7 - ELOC Commitment Note Payable	Sep. 30, 2024
Notes to Financial Statements
Convertible Promissory Notes Payable [Text Block]	Note 7 – ELOC Commitment Note Payable In June 2024, we entered into the ELOC Purchase Agreement establishing an equity line of credit for the right to sell shares of our common stock to the Purchaser. As consideration for the Purchaser’s irrevocable commitment to purchase shares of our common stock upon the terms of and subject to satisfaction of the conditions set forth in the ELOC Purchase Agreement, concurrently with the execution and delivery of the ELOC Purchase Agreement, we issued a convertible promissory note, or the ELOC Commitment Note, to the Purchaser in the amount of $350,000. The ELOC Commitment Note matures on June 26, 2025 and will bear interest at 5% per annum on a 365-day basis, due and payable on June 26, 2025. The Purchaser, in its sole discretion and upon written notice to us may convert all or a portion of the entire unpaid principal balance of the ELOC Commitment Note, together with all accrued and unpaid interest, if any, or the Conversion Amount, into a number of shares of our common stock equal to (x) the Conversion Amount divided by, as of the date of such conversion notice or other date of determination, the lesser of (i) a 20% discount to the lowest intraday sale price of our common stock as traded on the principal market on June 26, 2024 and (ii) a 20% discount to the lowest intraday sale price of our common stock as traded on the principal market during the 20 trading days immediately preceding the date of such conversion notice, subject to adjustment as provided in the terms of the ELOC Commitment Note. The ELOC Commitment Note in its entirety had an estimated fair value of $0.6 million at issuance, while the ELOC Commitment Note conversion option was required to be bifurcated as a separate derivative liability upon issuance. As a result, we recorded the fair value of the conversion option feature in the amount of $0.3 million as a derivative liability and $0.3 million as a ELOC Commitment Note payable in our condensed consolidated balance sheet. Because there was no consideration paid by the Purchaser in exchange for the ELOC Commitment Note, the entire initial fair value of both instruments was recorded to other expense in the amount of $0.6 million. The derivative is adjusted to fair value at each reporting period, with the change in the fair value recorded in change in fair value of derivatives that is a component of other income (expense) in our condensed consolidated statement of operations. For the three As of September 30, 2024, 1.4 million shares of Common Stock have been sold under the ELOC Purchase Agreement for net proceeds of $4.4 million. Additionally, as a result of our sales of Common Stock pursuant to the ELOC Purchase Agreement, we redeemed 705 Series C Preferred Shares as of September 30, 2024 for an aggregate redemption price of $1.1 million pursuant to the Company’s Certificate of Designations of Rights and Preferences of Series C Convertible Preferred Stock.

Note 8 - Common Stock Warrant L

Note 8 - Common Stock Warrant Liability	9 Months Ended
Note 8 - Common Stock Warrant Liability	Sep. 30, 2024
Notes to Financial Statements
Common Stock Warrant Liability [Text Block]	Note 8 – Common Stock Warrant Liability We account for common stock warrants in accordance with applicable accounting guidance provided in ASC Topic 480 - Distinguishing Liabilities from Equity In July 2024, we completed two private placements of Series C Preferred Stock and July 2024 Warrants (Refer to Note 13, “Mezzanine Equity and Stockholders' Equity - Accounting for the First and Second Private Placements ” for additional details). The July 2024 Warrants are exercisable upon the six month and one day anniversary of the issuance date, or the Initial Exercisability Date, and expire on the fifth The July 2024 warrants had an initial fair value of $10.8 million upon issuance. As of September 30, 2024, the change in the estimated fair value of the July 2024 warrants was $2.2 million and was recorded in the condensed consolidated statement of operation for the three and nine months ended September 30, 2024.

Note 9 - Senior Secured and Sen

Note 9 - Senior Secured and Senior Unsecured Notes Payable	9 Months Ended
Note 9 - Senior Secured and Senior Unsecured Notes Payable	Sep. 30, 2024
Notes to Financial Statements
Senior Secured Promissory Notes Payable [Text Block]	Note 9 – Senior Secured and Senior Unsecured Notes Payable On June 25, 2024, we issued senior secured notes with an aggregate principal amount of $0.3 million. The maturity date of such notes was June 25, 2025, unless extended at the holder’s option in accordance with the terms of the notes. On June 28, 2024, we issued additional senior secured notes with an aggregate principal amount of $0.1 million. The maturity date of such notes was June 28, 2025, unless extended at the holder’s option in accordance with the terms of the notes. We collectively refer to such senior secured notes due 2025 as the June Senior Secured Notes. The aggregate gross proceeds from the issuances of the June Senior Secured Notes were $0.35 million. The June Senior Secured Notes include a 15% original issue discount. The June Senior Secured Notes bear interest at 10% per annum on a 360-day and twelve 30-day month basis, payable monthly in cash and in arrears on each Interest Date (as defined in the June Senior Secured Notes) and such interest compounds each calendar month. On July 3, 2024, we agreed to issue and sell to (i) an institutional investor an aggregate principal amount of $0.1 million in senior secured notes, or the July Secured Note, and (ii) an additional institutional investor an aggregate principal amount of $0.1 million in senior unsecured notes, or the July Unsecured Note, and together with the July Secured Note, the July 2024 Notes, for aggregate gross proceeds of $0.2 million. The July 2024 Notes include a 15% original issue discount and had a maturity date of July 3, 2025, unless extended at the holder’s option in accordance with the terms of the July 2024 Notes. The July Secured Note was secured by first-priority security interests in all of our assets then presently existing, and constitutes a valid, first priority security interest in all of the assets that we later-acquire, as further defined in the July 2024 Secured Note. Certain conversion and redemption features of the June Senior Secured Notes and the July 2024 Notes would typically be considered derivatives that would require bifurcation. In lieu of bifurcating various features in the agreement, we elected the fair value option for the June Senior Secured Notes and the July 2024 Notes and recorded the changes in the fair value within the accompanying condensed consolidated statements of operations at the end of each reporting period. The excess of the initial fair value of $0.4 million of the June Senior Secured Notes over the proceeds received of $0.35 million was recorded to other expense in the amount of $41,000 during the three months ended June 30, 2024. The excess of the initial fair value of $0.23 million of the July 2024 Notes over the proceeds received of $0.2 million was recorded to other expense in the amount of $27,000 during the three months ended September 30, 2024. We used the proceeds from our First PIPE to extinguish the June Senior Secured Notes and July 2024 Notes. Immediately prior to the extinguishment, the combined fair value of the June Senior Secured Notes and the July 2024 Notes was $0.7 million. We determined that the fair value of the instruments issued, which totaled $0.7 million, represents the fair value of the instruments extinguished, and therefore there was no gain or loss recognized on extinguishment. Refer to Note 13, “Mezzanine Equity and Stockholders' Equity - Accounting for the First and Second Private Placements ” for additional details. As of September 30, 2024, there are no June Senior Secured Notes or July 2024 Notes outstanding.

Note 10 - Loans Payable

Note 10 - Loans Payable	9 Months Ended
Note 10 - Loans Payable	Sep. 30, 2024
Notes to Financial Statements
Short-Term Debt [Text Block]	Note 10 – Loans Payable In August 2024, we entered into an insurance premium financing and security agreement with IPFS Corporation. Under the agreement, we financed $0.5 million of certain premiums at a fixed annual interest rate. Payments of approximately are due monthly from August 2024 through May 2025. As of September 30, 2024, the outstanding principal of the loan was $0.4 million. In June 2023, we entered into an insurance premium financing and security agreement with IPFS Corporation. Under the agreement, we financed million of certain premiums at a fixed annual interest rate. Payments of approximately were due monthly from July 2023 through April 2024. As of December 31, 2023, the outstanding principal of the loan was $0.2 million. The balance of the loan was repaid during the first quarter of 2024.

Note 11 - Other Current Liabili

Note 11 - Other Current Liabilities	9 Months Ended
Note 11 - Other Current Liabilities	Sep. 30, 2024
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	Note 11 - Other Current Liabilities In 2008, we entered into an Amended and Restated License Agreement with Philip Morris USA, Inc., or PMUSA, with respect to the U.S., or the U.S. License Agreement, and, as PMUSA had assigned its ex-U.S. rights to Philip Morris Products S.A., or PMPSA, effective on the same date and on substantially the same terms and conditions, we entered into a license agreement with PMPSA with respect to rights outside of the U.S., which we refer to, together with the U.S. License Agreement, as the PM License Agreements. Amendment No. 1 to the Amended and Restated License Agreement with Philip Morris USA for Aerosolization Technology On January 16, 2024, we entered into Amendment No. 1 to the U.S. License Agreement, effective as of January 17, 2024, or the U.S. License Agreement Amendment, which amended the U.S. License Agreement. The U.S. License Agreement licenses U.S. intellectual property rights to us in respect of our former acute pulmonary care platform that was globally outlicensed to the Licensee in August 2022. Pursuant to the U.S. License Agreement Amendment, we agreed to pay PMUSA (i) $100,000 by January 18, 2024, or the PMUSA Upfront Payment, (ii) $400,000 no later than the earlier of (a) July 1, 2024 or (b) the Company receiving a specified amount of net proceeds from debt or equity financings occurring on or after January 17, 2024 and (iii) up to an aggregate of $1.4 million upon the achievement of certain development and regulatory milestones, which milestone payments are expected to be funded from corresponding milestone payments received from the Licensee. Additionally, under the U.S. License Agreement Amendment, the parties extinguished and released their respective rights, obligations and claims in respect of quarterly payments under Section 7.3 of the U.S. License Agreement as in effect immediately prior to January 17, 2024. The U.S. License Agreement Amendment also grants PMUSA the right to terminate the U.S. License Agreement upon 30 days prior written notice to us if we have not paid a milestone payment to PMUSA by January 1, 2028. Amendment No. 2 to the Amended and Restated License Agreement with Philip Morris USA for Aerosolization Technology As a result of us not paying the $400,000 payable to PMUSA by July 1, 2024, PMUSA issued a notice of default to us dated July 17, 2024. Such notice of default informed us that to avoid termination of the US License Agreement and a collection action via arbitration, we must pay the $400,000 by September 15, 2024. We did not pay $400,000 to PMUSA by September 15, 2024 as specified in the notice of default. Rather, on October 28, 2024, we entered into Amendment No. 2 to the License Agreement with PMUSA, or the Second PMUSA License Amendment, to further amend the PMUSA License Agreement. Pursuant to the Second PMUSA License Amendment, we agreed to pay PMUSA (i) $200,000 no later than October 29, 2024, or the PMUSA Initial Payment, and (ii) $200,000 no later than November 15, 2024, or the PMUSA Deferred Payment, plus interest on the PMUSA Deferred Payment at the rate of 18% per annum for the period beginning on July 2, 2024, and ending on the date of payment. In the event any balance on the PMUSA Deferred Payment (including accrued interest) remains unpaid after November 15, 2024, interest on such remaining balance will then accrue at the rate of 27% per annum until December 31, 2024 or the date of payment, whichever is earlier. In the event any balance (including accrued interest) on the PMUSA Deferred Payment remains unpaid after December 31, 2024, interest shall then accrue at the rate of 36% per annum on such balance until the date of payment. Amendment No. 1 to the License Agreement with Philip Morris Products for Aerosolization Technology On January 16, 2024, we also entered into Amendment No. 1 to the License Agreement with PMPSA, effective as of January 17, 2024, or the PMPSA License Amendment, which amended the License Agreement, dated March 28, 2008, between us and PMPSA, or the PMPSA License Agreement. The PMPSA License Agreement licenses ex-U.S. intellectual property to us in respect of our former acute pulmonary care platform that was globally outlicensed to the Licensee in August 2022. Pursuant to the PMPSA License Amendment, we agreed to pay PMPSA (i) $75,000 by January 19, 2024, or the PMPSA Upfront Payment, (ii) $325,000 no later than the earlier of (a) July 1, 2024 or (b) the Company receiving a specified amount of net proceeds from debt or equity financings occurring on or after January 17, 2024 (together with the PMPSA Upfront Payment, the Fixed Payments) and (iii) up to an aggregate of $1.4 million upon the achievement of certain development and regulatory milestones, which milestone payments are expected to be funded from corresponding milestone payments received from the Licensee. Additionally, but contingent upon our timely payment of the Fixed Payments, the parties extinguished and released their respective rights, obligations and claims in respect of quarterly payments under Section 6.2 of the PMPSA License Agreement as in effect immediately prior to January 17, 2024. Amendment No. 2 to the License Agreement with Philip Morris Products for Aerosolization Technology We did not pay $325,000 to PMPSA by July 1 as required by the PMPSA License Amendment. Rather, on July 31, 2024, we entered into Amendment No. 2 to the License Agreement with PMPSA, or the Second PMPSA License Amendment, to further amend the PMPSA License Agreement. Pursuant to the Second PMPSA License Amendment, we agreed to pay PMPSA (i) $200,000 no later than August 2, 2024, or the PMPSA Initial Payment, and (ii) $125,000 no later than November 15, 2024, or the PMPSA Deferred Payment, plus interest on the PMPSA Deferred Payment at the rate of 18% per annum for the period beginning on July 2, 2024, and ending on the date of payment. In the event any balance on the PMPSA Deferred Payment (including accrued interest) remains unpaid after November 15, 2024, interest on such remaining balance will then accrue at the rate of 27% per annum until December 31, 2024 or the date of payment, whichever is earlier. In the event any balance (including accrued interest) on the PMPSA Deferred Payment remains unpaid after December 31, 2024, interest shall then accrue at the rate of 36% per annum on such balance until the date of payment. Accounting for the PMUSA and PMPSA Payments We accounted for these payments as a recognized subsequent event for 2023 in accordance with applicable accounting guidance provided in ASC Topic 855, Subsequent Events. , the remaining liability related to PMUSA and PMPSA is $0.5 million and is recorded in other current liabilities. During October 2024, the PMUSA Initial Payment of $200,000 was paid. The PMUSA Deferred Payment of $200,000 and the PMPSA Deferred Payment of $125,000 have not been paid as of November 25, 2024.

Note 12 - Restructured Debt Lia

Note 12 - Restructured Debt Liability	9 Months Ended
Note 12 - Restructured Debt Liability	Sep. 30, 2024
Notes to Financial Statements
Long-Term Debt [Text Block]	Note 12 – Restructured Debt Liability On October 27, 2017, we and Deerfield entered into the Milestone Agreement pursuant to which (i) promissory notes evidencing a loan with affiliates of Deerfield in the aggregate principal amount of $25.0 million and (ii) warrants to purchase up to 10 shares of our common stock at an exercise price of $2,124,360 per share held by Deerfield were cancelled in consideration for (x) a cash payment in the aggregate amount of $2.5 million, (y) 27 shares of common stock, representing 2% of fully-diluted shares outstanding (as defined in the Milestone Agreement) on the closing date, and (z) the right to receive certain milestone payments, or Milestone Payments, based on achievement of specified AEROSURF development and commercial milestones, which, if achieved, could potentially total up to $15.0 million. In addition, a related security agreement, pursuant to which Deerfield held a security interest in substantially all of our assets, was terminated. We established a $15.0 million long-term liability for the contingent milestone payments potentially due to Deerfield under the Milestone Agreement. The liability was recorded at the full value of the contingent milestones and was to be carried at full value until the milestones were achieved and paid or the milestones were not achieved and the liability was written off as a gain on debt extinguishment. As of , the restructured debt liability balance was $15.0 million. On January 24, 2024, we and Deerfield entered into an Exchange and Termination Agreement wherein Deerfield agreed to terminate its rights to receive the Milestone Payments. Pursuant to the Exchange and Termination Agreement, Deerfield agreed to terminate its rights to receive the Milestone Payments and all related rights and obligations in respect of such Milestone Payments in exchange for (i) cash in the aggregate amount of $0.2 million, $0.1 million of which was paid on January 24, 2024 and $0.1 million of which is included in accrued expenses and will be paid no later than the earlier to occur of (a) January 24, 2025 and (b) us receiving a specified amount of gross proceeds from debt or equity financings occurring on or after January 24, 2024, and (ii) an aggregate of 33,793 shares of our common stock, par value $0.001 per share. The shares of the common stock were issued to Deerfield in a transaction exempt from registration pursuant Section 4(a)(2) of the Securities Act of 1933. Contemporaneously with the execution of the Exchange and Termination Agreement, we and Deerfield entered into a Registration Rights Agreement pursuant to which we have agreed to, among other matters, register for resale with the SEC the shares of the common stock issued to Deerfield pursuant to the Exchange and Termination Agreement. On February 14, 2024, we filed a resale registration statement on Form S-3 (File No. 333-277073) with respect to 33,793 shares of our common stock, which was amended on April 17, 2024. Such resale registration statement was declared effective by the SEC on April 19, 2024. The Exchange and Termination Agreement was accounted for as an extinguishment of debt in accordance with ASC Topic 470, Debt – Modifications and Extinguishments million non-cash gain on debt extinguishment during the nine months ended consisting of the difference between the $15.0

Note 13 - Mezzanine Equity and

Note 13 - Mezzanine Equity and Stockholders' Equity	9 Months Ended
Note 13 - Mezzanine Equity and Stockholders' Equity	Sep. 30, 2024
Notes to Financial Statements
Equity [Text Block]	Note 13 – Mezzanine Equity and Stockholders’ Equity First Private Placement On July 18, 2024, we entered into a Securities Purchase Agreement, or the First Purchase Agreement, with the buyers named therein, pursuant to which we agreed to the private placement, or the First PIPE, of (i) 16,099 shares, or the Preferred Shares, of our Series C Convertible Preferred Stock, par value $0.001 per share, or the Series C Preferred Stock, and (ii) warrants, or the July 2024 Warrants, to acquire up to the aggregate number of 3,440,631 additional shares of our common stock for aggregate gross proceeds of approximately $12.9 million of which $9.5 million was paid through the cancellation and extinguishment of certain securities as further described below. Additionally, we issued 161 Preferred Shares and 62,892 July 2024 Warrants as compensation for certain placement agent fees and expenses. We also reimbursed the lead buyer for certain fees and expenses of counsel in accordance with the terms of the First Purchase Agreement. We agreed to seek stockholder approval for the issuance of all of the shares of our common stock issuable upon conversion of the Preferred Shares and exercise of the July 2024 Warrants in connection with the First PIPE in accordance with the rules and regulations of the Nasdaq Stock Market, which approval was obtained on September 24, 2024. Series C Preferred Stock The terms of the Series C Preferred Stock are as set forth in the Series C Certificate of Designation of Series C Preferred Stock, as filed with the Delaware Secretary of State and effective on July 19, 2024. The Series C Certificate of Designation authorizes a total of 18,820 shares of Series C Preferred Stock with an initial conversion price of $3.74, or the Series C Preferred Conversion Price, which is subject to adjustment as provided in the Series C Certificate of Designation to no lower than $1.28. The Series C Preferred Stock has a stated value of $1,000 per share. Each share of Series C Preferred Stock is initially convertible into 267 shares of our common stock, subject to adjustment as provided in the Series C Certificate of Designation. No fractional shares will be issued upon conversion; rather any fractional share will be rounded up to the nearest whole share. From and after July 19, 2024, each holder of a share of Series C Preferred Stock is entitled to receive dividends, which are computed on the basis of a 360-day year and twelve 30-day months and will increase the stated value of the Series C Preferred Stock on each dividend date (as defined in the Series C Certificate of Designation). Dividends on the Series C Preferred Stock will accrue at 10.0% per annum and be payable by way of inclusion of the dividends in the Conversion Amount (as defined in the Series C Certificate of Designation) on each Conversion Date (as defined in the Series C Certificate of Designation) in accordance with the Series C Certificate of Designation or upon any redemption in accordance with the Series C Certificate of Designation or upon any required payment upon any Bankruptcy Triggering Event (as defined in the Series C Certificate of Designation). From and after the occurrence and during the continuance of any Triggering Event (as defined in the Series C Certificate of Designation), the accrual of the dividends will automatically be increased to 18.0% per annum. The Preferred Conversion Price is subject to adjustment upon the occurrence of specified events and subject to price-based adjustment in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transaction involving our common stock at a price below the then-applicable Preferred Conversion Price, as described in further detail in the Series C Certificate of Designation. July 2024 Warrants The July 2024 Warrants are exercisable upon the six month and one day anniversary of the issuance date, or the Initial Exercisability Date, and expire on the fifth anniversary of the Initial Exercisability Date and will have an exercise price of $4.11 per share, subject to customary adjustments. Cancellation and Extinguishment of Certain Securities In connection with the First PIPE, $9.5 million of the aggregate gross proceeds was paid through the cancellation and extinguishment of certain holders’ (x) outstanding principal amount, conversion/exchange premiums and all accrued interest and dividends thereon under our (i) Senior Convertible Notes, (ii) the June Senior Secured Notes, (iii) the July Secured Note, and (iv) the July Unsecured Note, and (y) 5,500 shares of the Series B Preferred Stock. Related Party Participation Our CEO and CMO each participated in the First PIPE, with Mr. Fraser making a $15,000 purchase to receive 19 shares of Series C Preferred Stock and 4,011 July 2024 Warrants and Dr. Simonson making a $10,000 purchase to receive 13 shares of Series C Preferred Stock and 2,674 July 2024 Warrants. Neither Mr. Fraser nor Dr. Simonson have received any redemption payments or payments of accrued dividends, nor have they converted any shares of Series C Preferred Stock. Second Private Placement On July 26, 2024, we entered into a Securities Purchase Agreement, or the Second Purchase Agreement, with the buyer named therein, pursuant to which we agreed to a second tranche of the private placement, or the Second PIPE, of (i) 1,250 Preferred Shares, and (ii) July 2024 Warrants to acquire up to the aggregate number of 267,380 additional shares of our common stock for aggregate gross proceeds of approximately $1.0 million. Additionally, we issued 30 Preferred Shares and 8,022 July 2024 Warrants as compensation for certain placement agent fees and expenses. We also reimbursed the lead buyer for certain fees and expenses of counsel in accordance with the terms of the Second Purchase Agreement. We agreed to seek stockholder approval for the issuance of all of the shares of our common stock issuable upon conversion of the Preferred Shares and exercise of the July 2024 Warrants in connection with the Second PIPE in accordance with the rules and regulations of the Nasdaq Stock Market. The rights and preferences of the Series C Preferred Stock issued in connection with the Second PIPE, including the terms pursuant to which they are convertible into our common stock, are consistent with the rights and preferences of the Series C Preferred Stock issued in connection with the First PIPE. Similarly, the terms of the warrants issued in connection with the Second PIPE are consistent with the terms of the warrants issued in connection with the First PIPE. Accounting for the First and Second Private Placements The July 2024 Warrants are considered a freestanding financial instrument as they are separable and legally detachable from the Series C Preferred Stock. The July 2024 Warrants have been classified as a liability in the Company’s condensed consolidated balance sheet because they include a put option election available to the holders that is contingently exercisable if the Company enters into a change of control transaction, or the Change of Control Put. If the Change of Control Put is exercised by the holder of a July 2024 Warrant, they may elect to receive cash as determined by the Black Scholes pricing model, based on terms and timing specified in the July 2024 Warrants. The potential for a cash settlement for the July 2024 Warrants is outside the control of the Company, and in accordance with U.S. GAAP, requires the July 2024 Warrants to be treated as financial liabilities measured at fair value through profit or loss. Net cash proceeds from the issuance of 4,255 Series C Convertible Preferred Stock and 909,094 July 2024 Warrants in the First Private Placement totaled $3.1 million, net of lead buyer reimbursements of $0.3 million. The net cash proceeds were allocated first to the July 2024 Warrants based on their fair value which totaled $2.6 million, and the remaining $0.5 million was allocated to the Series C Preferred Stock using the residual method of allocation. Net cash proceeds from the issuance of 1,250 Series C Convertible Preferred Stock and 267,380 July 2024 Warrants in the Second Private Placement totaled $975,000, net of lead buyer reimbursement of $25,000. The net cash proceeds were allocated first to the July 2024 Warrants based on their fair value which totaled $726,000, and the remaining $249,000 was allocated to the Series C Preferred Stock using the residual method of allocation. The Company accretes to Series C Preferred Stock against additional paid-in capital as a deemed dividend for the difference between the initial net carrying value and the full redemption price of $1,000 per share. The Company uses the effective interest method to calculate the accretion amount for each period. Upon issuance of the Series C Preferred Stock, the Company was not solely in control of the redemption of the shares of Series C Preferred Stock as the Series C Preferred Stock has multiple redemption features that are outside of our control, including time-based maturity redemption and change of control redemption. Since the redemption of the Series C Preferred Stock was not solely in the control of the Company, the shares of Series C Preferred Stock are classified within mezzanine equity. In connection with the First PIPE, we issued 2,080 shares of Series C Preferred Stock and 444,536 July 2024 Warrants for the cancellation and extinguishment of certain holders’ outstanding principal amount, conversion/exchange premiums and all accrued interest thereon under our Senior Convertible Notes with a net carrying value of $1.2 million. In addition, the associated derivative liability which had a fair value of $0.3 million was also extinguished. The fair value of the instruments issued were determined based on the fair value of the July 2024 Warrants and the residual value determined for the Series C Preferred Stock as described above. The difference between the carrying value of the extinguished instruments and the fair value of the instruments issued totaling $1.5 million was $46,000 and recorded as gain on debt extinguishment. In addition, we issued 966 shares of Series C Preferred Stock and 206,277 July 2024 Warrants for the cancellation and extinguishment of certain holders’ outstanding principal amount, conversion/exchange premiums and all accrued interest thereon under our June Senior Secured Notes, July Secured Note, and July Unsecured Note, which are carried at fair value. The Company determined that the fair value of the instruments issued, which totaled $0.7 million represents the fair value of the instruments extinguished, and therefore there was no gain or loss recognized on the extinguishment. The fair value of the instruments issued were determined based on the fair value of the July 2024 Warrants and the residual value determined for the Series C Preferred Stock as described above. Also in connection with the First PIPE, we issued 8,798 shares of Series C Preferred Stock and 1,880,724 July 2024 Warrants for the cancellation and extinguishment of 5,500 shares of the Series B Preferred Stock with a net carrying value of $7.0 million. The fair value of the instruments issued were determined based on the fair value of the July 2024 Warrants and the residual value determined for the Series C Preferred Stock as described above. The difference of $0.6 million between the carrying value of the extinguished instruments totaling $7.0 million and the fair value of the instruments issued totaling $6.4 million was credited to retained earnings and adjusted to net loss per common share for the three and nine months ended September 30, 2024. We incurred approximately $0.8 million of legal, placement and professional fees in connection with the First and Second PIPEs. In addition, we issued 191 Series C Preferred Shares and 70,914 July 2024 Warrants as compensation for certain placement agent fees and expenses. The fair value of the instruments issued for compensation were determined based on the fair value of the July 2024 Warrants and the residual value determined for the Series C Preferred Stock as described above, which amounted to $0.2 million and were accounted for as issuance costs. The issuance costs totaling $1.1 million were allocated to all of the Series C Preferred Stock and July 2024 Warrants issued in the First and Second PIPEs based on their fair values and residual value. Issuance costs allocated to the July 2024 Warrants totaling $0.9 million were expensed immediately and issuance costs allocated to the Series C Preferred Stock totaling $0.2 million were recorded as a reduction of the net carrying value of the Series C Preferred Stock at inception as additional discount, which will be accreted against additional paid-in capital as a deemed dividend using the interest method. Conversions and Redemptions of Series C Preferred Stock During the three months ended September 30, 2024, 1,116 shares of Series C Convertible Preferred Stock and $55,000 of accrued and unpaid dividends were converted into 313,071 shares of common stock. Upon conversion, the carrying value of $154,000 of the Series C Preferred Stock was reclassified to common stock $0.001 par value and additional paid-in capital. There was no gain or loss recognized on the transaction as the shares were converted in accordance with the original terms of the Certificate of Designation of Series C Preferred Stock. During the three months ended September 30, 2024, 706 shares of Series C Convertible Preferred Stock were redeemed for $0.8 million in cash at their stated value per share of $1,000 plus a 20% premium in connection with the Equity Line Mandatory Redemption. In addition, $0.3 million was paid for accrued and unpaid dividends. The excess of the consideration paid over the carrying value of the Series C Preferred Stock redeemed was accounted for as a deemed dividend and resulted in an increase in net loss per common share during the three and nine months ended September 30, 2024. Common Stock Purchase Agreement In June 2024, we entered into the ELOC Purchase Agreement establishing an equity line of credit with the Purchaser, whereby we have the right, but not the obligation, to sell to the Purchaser, and the Purchaser is obligated to purchase, up to $35 million of newly issued shares of our common stock. Over the 36-month period from and after the Commencement Date, we will control the timing and amount of any sales of Common Stock to the Purchaser. Actual sales of shares of our common stock to the Purchaser under the ELOC Purchase Agreement will depend on a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price of our common stock and determinations by us as to the appropriate sources of funding and our operations. For the three months ended September 30, 2024, we sold 1.4 million shares of Common Stock under the ELOC Purchase Agreement for gross proceeds of $4.4 million, $0.7 million of which is included in prepaid expenses and other assets as of September 30, 2024 for gross proceeds for sales made during the quarter for which we had not yet received the cash. Pursuant to the Company’s Certificate of Designations of Rights and Preferences of Series C Convertible Preferred Stock, we are required to use 30% of the proceeds from sales pursuant to the ELOC Purchase Agreement to pay outstanding Series C Preferred Stock dividends and to redeem Series C Preferred Stock at a 20% premium to the $1,000 stated price per share. For the three months ended September 30, 2024, we paid an aggregate redemption price of $1.1 million with $0.3 million applied to accrued and unpaid dividends and $0.8 million to redeem 705 Series C Preferred Shares. During October 2024, we paid an additional aggregate redemption price related to ELOC Purchase Agreement sales during the quarter of $0.2 million with approximately $50,000 applied to accrued and unpaid dividends and $0.15 million to redeem 133 Series C Preferred Shares. Inclusive of the additional redemptions paid after quarter end, we received net proceeds from the shares sold under the ELOC Purchase Agreement of $3.1 million. We have determined that the put option in the ELOC Purchase Agreement is a derivative within the scope of ASC Topic 815, Derivatives and Hedging, Asset Purchase Agreement with Varian Biopharmaceuticals On April 2, 2024, we entered into the Asset Purchase Agreement with Varian. Pursuant to the Asset Purchase Agreement, we purchased all of the assets of Varian’s business associated with the Licence Agreement, which includes the Licence Agreement, all rights in molecules and compounds subject to the Licence Agreement, know-how and inventory of drug substance, or the Transferred Assets. We also assumed all liabilities arising on or after April 2, 2024, relating to the research, development, manufacturing, registration, commercialization, use, handling, supply, storage, import, export or other disposition or exploitation of any and all products associated with the Transferred Assets. In consideration of the purchase of the Transferred Assets, (i) on April 2, 2024, we issued a total of 5,500 shares of our Series B Preferred Stock, par value $0.001 per share, or the Series B Preferred Stock, to certain creditors of Varian and (ii) agreed to pay up to $2.3 million in milestone payments upon the achievement of certain regulatory and clinical development milestones with our option to pay such milestone payments either in cash or our common stock. The Asset Purchase Agreement contains customary representations and warranties, covenants, closing conditions and indemnification provisions for a transaction of this nature, including, without limitation, confidentiality and non-compete undertakings by Varian. The fair value of the consideration transferred for the 5,500 shares of our Series B Preferred Stock was $7.0 million. Because the assets acquired do not meet the definition of a business, and the assets have not reached technological feasibility and have no alternative future use, we expensed the consideration paid as research and development expense in the consolidated statements of operations. As of September 30, 2024, we have not recorded a liability or expense related to contingent consideration for future milestone payments to Varian, as the achievement of such milestones has not occurred and was not deemed probable. Series B Preferred Stock The terms of the Series B Preferred Stock are as set forth in the Series B Certificate of Designation of Series B Preferred Stock, as filed with the Delaware Secretary of State and effective on April 3, 2024. The Series B Certificate of Designation authorizes a total of 5,500 shares of Series B Preferred Stock, or the Series B Preferred Stock, with an initial conversion price of $6.4854, or the Series B Preferred Conversion Price, which is subject to adjustment as provided in the Series B Certificate of Designation to no lower than $1.2978. The Series B Preferred Stock has a stated value of $1,000 per share. Each share of Series B Preferred Stock is initially convertible into 155 shares of our common stock, subject to adjustment as provided in the Series B Certificate of Designation. No fractional shares will be issued upon conversion; rather any fractional share will be rounded up to the nearest whole share. Upon issuance of the Series B Preferred Stock, the Company was not solely in control of the redemption of the shares of Series B Preferred Stock as the Series B Preferred Stock has multiple redemption features that are outside of our control, including time-based maturity redemption and change of control redemption. Since the redemption of the Series B Preferred Stock was not solely in the control of the Company, the shares of Series B Preferred Stock are classified within mezzanine equity. The shares of Series B Preferred Stock were recorded at fair value of $7.0 million partially offset by issuance costs of $68,000. Because this initial carrying value of the Series B Preferred Stock is higher than the maturity redemption price (i.e., the stated value of $5.5 million with the 10% per annum dividend over the period from issuance until maturity on January 2, 2025), no accretion of Series B Preferred Stock dividends will be recorded. The Series B Preferred Stock could become redeemable at higher values than the initial carrying value under the standard and customary triggering events or a redemption in the event of a change of control, in each case, pursuant to the terms of the Series B Certificate of Designations, but these are not probable of occurrence as of June 30, 2024. As of September 30, 2024, there are no shares of Series B Preferred Stock outstanding. (See the section titled, Note 13 “Mezzanine Equity and Stockholders’ Equity - First Private Placement”). April 2023 Public Offering On April 20, 2023, we entered into an underwriting agreement with Ladenburg Thalmann & Co. Inc., or Ladenburg, as the sole underwriter relating to a public offering, or the April 2023 Offering, of an aggregate of 204,779 units with each unit consisting of one share of common stock and a warrant, or the April 2023 Warrants. The April 2023 Warrants are immediately exercisable for shares of common stock at a price of $52.74 per share and expire five In addition, Ladenburg exercised in full a 45-day option, or the Overallotment Option, to purchase up to 30,717 additional shares of common stock and/or warrants to purchase up to 30,717 additional shares of common stock. The closing of the April 2023 Offering occurred on April 24, 2023, inclusive of the Overallotment Option. The offering price to the public was $52.74 per unit resulting in gross proceeds to us of approximately $12.4 million. After deducting underwriting discounts and commissions and other estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the April 2023 Warrants issued pursuant to this April 2023 Offering, the net proceeds to us were approximately $10.8 million. We have determined that the appropriate accounting treatment under ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging January 2023 Warrant Exercise Inducement Offer Letters On January 20, 2023, we entered into warrant exercise inducement offer letters with certain holders of certain of our: (i) warrants issued in December 2019 to purchase 88 shares of common stock with an exercise price of $10,881.00 per share; (ii) warrants issued in May 2020 to purchase 311 shares of common stock with an exercise price of $7,177.50 per share, and (iii) warrants issued in March 2021 to purchase 4,945 shares of common stock with an exercise price of $3,240.00 per share (collectively, the January 2023 Existing Warrants). Pursuant to the terms of the inducement letters, we agreed to amend the January 2023 Existing Warrants by lowering the exercise price of the January 2023 Existing Warrants to $180.00 per share. Additionally, the exercising holders agreed to exercise for cash all of their January 2023 Existing Warrants to purchase an aggregate of 5,343 shares of common stock in exchange for our agreement to issue to such exercising holders new warrants, or the January 2023 New Warrants, to purchase up to an aggregate of 10,686 shares of common stock. We received aggregate gross and net proceeds of approximately $1.0 million and $0.7 million, respectively, from the exercise of the January 2023 Existing Warrants by the exercising holders. Each January 2023 New Warrant is exercisable into shares of common stock at a price per share of $193.68, was exercisable six months following its date of issuance, or the January 2023 Initial Exercise Date, and will expire on the fifth February 2023 Warrant Exercise Inducement Offer Letter On February 21, 2023, we entered into a warrant exercise inducement offer letter with Panacea Venture Healthcare Fund I, L.P., a holder of certain of our: (i) warrants issued in July 2018 to purchase 70 shares of common stock with an exercise price of $10,800.00 per share; (ii) warrants issued in December 2018 to purchase 554 shares of common stock with an exercise price of $10,935.00 per share; (iii) warrants issued in December 2019 to purchase 307 shares of common stock with an exercise price of $10,881.00 per share; and (iv) warrants issued in May 2020 to purchase 307 shares of common stock with an exercise price of $7,177.50 per share (collectively, the February 2023 Existing Warrants). Pursuant to the terms of the inducement letter, we agreed to amend the February 2023 Existing Warrants by lowering the exercise price of the February 2023 Existing Warrants to $127.08 per share. Additionally, Panacea agreed to exercise for cash all of their February 2023 Existing Warrants to purchase an aggregate of 1,236 shares of common stock in exchange for our agreement to issue to Panacea new warrants, or the February 2023 New Warrants, to purchase up to an aggregate of 2,472 shares of common stock. We received aggregate gross and net proceeds of approximately $0.2 million and $0.1 million, respectively, from the exercise of the February 2023 Existing Warrants by Panacea. Each February 2023 New Warrant is exercisable into shares of common stock at a price per share of $193.68, was exercisable six months following its date of issuance, or the February 2023 Initial Exercise Date, and will expire on the fifth Accounting for the January 2023 and February 2023 Warrant Exercise Inducement Offer Letters The amendment of the January 2023 Existing Warrants and the February 2023 Existing Warrants by lowering the exercise prices and issuing the January 2023 New Warrants and the February 2023 New Warrants is considered a modification of the January 2023 Existing Warrants and the February 2023 Existing Warrants under the guidance of ASU 2021-04. The modification is consistent with the “Equity Issuance” classification under that guidance as the reason for the modification was to induce the holders to cash exercise their warrants, resulting in the imminent exercise of the January 2023 Existing Warrants and the February 2023 Existing Warrants, which raised equity capital and generated net proceeds for us of approximately $0.7 million and $0.1 million, respectively. The total fair value of the consideration of the modification includes the incremental fair value of the January 2023 Existing Warrants and the February 2023 Existing Warrants (determined by comparing the fair values immediately prior to and immediately after the modification) and the initial fair value of the January 2023 New Warrants and the February 2023 New Warrants. The fair values were calculated using the Black-Scholes model and we determined that the total fair value of the consideration related to the modification of the January 2023 Existing Warrants and the February 2023 Existing Warrants, including the initial fair value of the January 2023 New Warrants and the February 2023 New Warrants, was $1.2 million and $0.3 million, respectively. At-The-Market Program On November 9, 2023, we entered into the 2023 ATM Program with Ladenburg. We are not obligated to make any sales under the 2023 ATM Program. When we issue sale notices to Ladenburg, we designate the maximum amount of shares to be sold by Ladenburg daily and the minimum price per share at which shares may be sold. Ladenburg may sell shares by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, or in privately negotiated transactions. Sales under the 2023 ATM Program will be made pursuant to our “shelf” registration statement on Form S-3 (No. 333-261878) filed with the SEC on December 23, 2021, and declared effective on January 3, 2022, and a prospectus supplement related thereto. Either party may suspend the offering under the 2023 ATM Program by notice to the other party. The 2023 ATM Program will terminate upon the earlier of (i) the sale of all shares subject to the 2023 ATM Program or (ii) termination of the 2023 ATM Program in accordance with its terms. Either party may terminate the 2023 ATM Program at any time upon five business days' prior written notification to the other party in accordance with the related agreement. We agreed to pay Ladenburg a commission of 3% of the gross sales price of any shares sold pursuant to the 2023 ATM Program. The rate of compensation will not apply when Ladenburg acts as principal, in which case such rate shall be separately negotiated. We also agreed to reimburse Ladenburg for the fees and disbursements of its counsel in an amount not to exceed $60,000, in addition to certain ongoing disbursements of its legal counsel up to $3,000 per calendar quarter. During the nine months ended September 30, 2024 , we sold shares of our common stock under the 2023 ATM Program resulting in aggregate gross and net proceeds to us of approximately million.

Note 14 - Stock-based Compensat

Note 14 - Stock-based Compensation	9 Months Ended
Note 14 - Stock-based Compensation	Sep. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	Note 14 – Stock-Based Compensation We recognize expense in our interim unaudited condensed consolidated financial statements related to all stock-based awards granted to employees and non-employee directors based on their fair value on the date of grant. Compensation expense related to stock options is calculated using the Black-Scholes option-pricing model and is recognized ratably over the vesting period, which is typically three one three A summary of activity under our long-term incentive plans is presented below: (in whole numbers) Stock Options Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (In Yrs) Outstanding at January 1, 2024 15,400 $ 1,664.00 Reverse split adjustments - fractional share round ups 106 (91.91 ) Forfeited or expired (648 ) 2,044.85 Outstanding at September 30, 2024 14,858 $ 1,551.47 8.2 Vested and exercisable at September 30, 2024 7,286 $ 3,130.51 7.4 Vested and expected to vest at September 30, 2024 14,046 $ 1,561.94 8.1 (in whole numbers) Restricted Stock Units Shares Weighted- Average Grant Date Fair Value Outstanding at January 1, 2024 8,180 $ 52.49 Reverse split adjustments - fractional share round ups 67 (0.42 ) Vested (140 ) 912.01 Forfeited (228 ) 21.58 Outstanding at September 30, 2024 7,879 $ 37.68 The table below summarizes the total stock-based compensation expense included in the interim unaudited condensed consolidated statements of operations for the periods presented: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Research and development $ 32 $ 93 $ 114 $ 280 General and administrative 55 212 321 692 Total $ 86 $ 305 $ 434 $ 972 The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities are based upon the historical volatility of our common stock and other factors. We also use historical data and other factors to estimate option exercises and forfeiture rates. The risk-free interest rates are based upon the U.S. Treasury yield curve in effect at the time of the grant.

Note 15 - Licensing and Researc

Note 15 - Licensing and Research Funding Agreements	9 Months Ended
Note 15 - Licensing and Research Funding Agreements	Sep. 30, 2024
Notes to Financial Statements
Corporate Partnership, Licensing and Research Funding Agreements [Text Block]	Note 15 – Licensing and Research Funding Agreements Asset Purchase Agreement with Varian Biopharmaceuticals On April 2, 2024, we entered into the Asset Purchase Agreement with Varian. Pursuant to the Asset Purchase Agreement, we purchased all of the assets of Varian’s business associated with the Licence Agreement, which includes the Licence Agreement, all rights in molecules and compounds subject to the Licence Agreement, know-how and inventory of drug substance, or the Transferred Assets. We also assumed all liabilities arising on or after April 2, 2024, relating to the research, development, manufacturing, registration, commercialization, use, handling, supply, storage, import, export or other disposition or exploitation of any and all products associated with the Transferred Assets. In consideration of the purchase of the Transferred Assets, (i) on April 2, 2024, we issued a total of 5,500 shares of our Series B Preferred Stock to certain creditors of Varian and (ii) agreed to pay up to $2.3 million in milestone payments upon the achievement of certain regulatory and clinical development milestones with our option to pay such milestone payments either in cash or our common stock. The Asset Purchase Agreement contains customary representations and warranties, covenants, closing conditions and indemnification provisions for a transaction of this nature, including, without limitation, confidentiality and non-compete undertakings by Varian. The fair value of the consideration transferred for the 5,500 shares of our Series B Preferred Stock was $7.0 million. Because the assets acquired do not meet the definition of a business, and the assets have not reached technological feasibility and have no alternative future use, we expensed the consideration paid as research and development expense in the consolidated statements of operations. As of September 30, 2024, we have not recorded a liability or expense related to contingent consideration for future milestone payments to Varian, as the achievement of such milestones has not occurred and was not deemed probable. Entry into a Material Definitive Agreement In order to reduce expected costs with our contract research organization, Momentum Research, Inc., or MRI, on May 9, 2024, or the Effective Date, we entered into Amendment No. 1 to the Master Services Agreement and Work Order Nos. 11 and 12, or the Amendment, with MRI. The Amendment amends the Master Services Agreement we entered into with MRI on February 13, 2020, or the Original MSA, and the original Work Order Nos. 11 and 12 we entered into with MRI on June 1, 2023, collectively, the Original Work Orders. Under the Original MSA, we agreed to, among other things, engage MRI to provide non-exclusive research and development services, by executing individual work orders to be negotiated and specified in writing on terms agreed to by both parties on a later date. Under the terms of the Amendment, we agreed to, among other things, be responsible for certain management, regulatory strategy, and reporting obligations in connection with our SEISMiC Extension study and MRI agreed to fully perform its obligations under the Original Work Orders with respect to the SEISMiC Extension study, including performance of all services and delivery of all deliverables required by the Original Work Orders. Additionally, with respect to the SEISMiC C Study, MRI agreed to be responsible for certain regulatory submissions, as provided in the Amendment. Additionally, in consideration of and conditioned upon the payments described below, we and MRI each agreed to cancel and extinguish any and all amounts owed to MRI or us, respectively, each subject to the terms of the Amendment. The parties agreed that such cancellation and extinguishment shall not be construed as a waiver of claims by each party for breach of the Original MSA or either or both of the Original Work Orders other than for non-payment, nor a waiver of each party’s respective indemnification rights under the Original MSA. In consideration of MRI’s full performance of the Original Work Orders and cancellation of accrued expenses as described above, we agreed to, among other things, pay MRI $1.2 million in a series of scheduled payments through September 20, 2024, subject to the terms of the Amendment. If services were not completed by October 31, 2024, the parties agreed that MRI would continue its services until fully completed with no further compensation. In case of delayed payments, we agreed to pay MRI interest on any overdue amount from the due date until the date paid in full at a rate equal to 18% per annum. If the SEISMiC Extension study and the SEISMiC C Study are terminated prior to September 20, 2024, then the next payment due after termination will be made to MRI and remaining payments that would have become due automatically become no longer payable. Additionally, we agreed that, for a transaction consummated by December 31, 2027, we shall pay MRI an amount equal to 2% of istaroxime license fees, milestone payments, royalties, securities or other property that we actually collect in respect of any license of istaroxime that we grant to any unaffiliated third party on or after the Effective Date; net of all legal and financial advisory fees and expenses actually paid by us in respect of the associated license transaction. Further, we agreed that if we commercialize istaroxime ourselves in the United States or another region, we shall also pay MRI an amount equal to 2% of our net profit derived from direct sales of istaroxime to clients in our territory where sales occurred, as determined in our US GAAP financial statements. Pursuant to the Amendment, such payments on istaroxime sales will end when data and market exclusivity protection expires for istaroxime. Further, in connection with the first to occur of either a Change of Control (as defined in the Amendment) or the sale of all or substantially all of our rights in istaroxime not in the context of a Change of Control, we agree to pay MRI an amount equal to 2% of the sum of any cash and the fair market value of any securities or other property that we actually collect or receive that is attributable to our rights in istaroxime (subject to the terms of the Amendment), net of a ratable portion of certain fees and expenses as provided by the Amendment. After December 1, 2025, we have the right to buy out the amounts due under certain provisions of the Amendment. The foregoing descriptions of the Original MSA and Amendment are general descriptions only, do not purport to be complete descriptions of the rights and obligations of the parties thereunder, and are qualified in their entirety by reference to the terms of such agreements, which are filed as Exhibit 10.1 and 10.2, respectively, to this Quarterly Report on Form 10-Q. Term Sheet and Project Financing Agreement with Lee s (HK) In March 2020, we entered into a Term Sheet with Lee’s (HK), pursuant to which Lee’s (HK) provided financing for the development of AEROSURF. In August 2020, we entered into a Project Financing Agreement with Lee’s (HK), or the PF Agreement, formalizing the terms of the Term Sheet, and under which we received payments totaling $2.8 million through October 2020. In November 2020, Lee’s (HK) provided notice of termination of additional funding under the PF Agreement, and we and Lee’s (HK) revised our plans for the continued development of AEROSURF. Lee’s (HK) agreed to continue the development of AEROSURF in Asia at its own cost. Lee’s (HK) agreed to fund an additional million to us in 2021 for certain transition and analytical services to be provided by us with respect to the development of AEROSURF, which will be considered “Project Expenses” under the terms of the PF Agreement. In 2021, we received payments totaling $1.0 million from Lee’s (HK) and no further amounts were due under the PF Agreement. Since the 2018 acquisition of CVie Investments Limited and CVie Therapeutics, istaroxime has become our primary focus for investment and execution due to what we believe represents a greater potential value opportunity for us and our stockholders. Since completing our Phase 2 study of lucinactant (KL4 surfactant) for patients with severe COVID-19 associated ARDS and lung injury in January 2022, in order to preserve resources for the highest priority programs, we have begun to reduce costs not already being performed by our licensee, Lee’s (HK) and Zhaoke, under the terms of our Original License Agreement. These costs include certain reductions in headcount dedicated to KL4 surfactant and the decommissioning of both our analytical and technical support laboratory, which previously conducted release testing of APIs and supportive research for our lyophilized and aerosolized KL4 surfactant, and our medical device development laboratory, which was previously used to conduct development activities and testing for our ADS technologies. To support the future development of our KL4 surfactant platform in markets outside of Asia, including the U.S., we are pursuing one or more licensing transactions. To repay the funds provided under the terms of the PF Agreement, until such time as we have repaid of the amounts funded by Lee’s (HK) for the development of AEROSURF, we will pay to Lee’s (HK) of all revenue amounts and payments received by us for any sale, divestiture, license or other development and/or commercialization of the KL4/AEROSURF patent portfolio, excluding (i) payments for bona fide research and development services; (ii) reimbursement of patent expenses and (iii) all amounts paid to us under the Original License Agreement, minus certain deductions and certain reductions for any payments made by us with respect to third party intellectual property not previously funded by Lee’s (HK). As of , the liability balance related to the payments under the PF Agreement was million and is recorded in other liabilities. A&R License Agreement with Lee s (HK) Previously, we were developing a KL4 surfactant platform, including AEROSURF (lucinactant for inhalation), to address a range of serious respiratory conditions in children and adults. In order to focus our resources on the development of our istaroxime pipeline, we suspended all internal AEROSURF clinical activities in November 2020, and, in January 2022 we began to reduce all other costs related to the KL4 surfactant platform that were not already being performed by our licensee, Lee’s (HK) and Zhaoke, under the terms of the Original License Agreement. On August 17, 2022, we entered into an Amended and Restated License, Development and Commercialization Agreement, or the A&R License Agreement, with Lee’s (HK) and Zhaoke effective as of August 9, 2022. We refer to Zhaoke and Lee’s (HK) together as the “Licensee.” The A&R License Agreement amends, restates, and supersedes the Original License Agreement. Under the A&R License Agreement, we granted to Licensee an exclusive license, with a right to sublicense, to develop, register, make, use, sell, offer for sale, import, distribute, and otherwise commercialize our KL4 surfactant products, including SURFAXIN®, the lyophilized dosage form of SURFAXIN, and aerosolized KL4 surfactant, in each case for the prevention, mitigation and/or treatment of any respiratory disease, disorder, or condition in humans worldwide, except for Andorra, Greece, and Italy (including the Republic of San Marino and Vatican City), Portugal, and Spain, or the Licensed Territory, which countries are currently exclusively licensed to Laboratorios Del Dr. Esteve, S.A., or Esteve. If and when the exclusive license granted to Esteve terminates as to any country, such country automatically becomes part of the Licensed Territory of Licensee. Under the Original License Agreement, Lee’s (HK) previously made an upfront payment to us of $1.0 million. Pursuant to the terms of the A&R License Agreement, we may also receive up to $78.9 million in potential clinical, regulatory, and commercial milestone payments. We are also entitled to receive a low double-digit percentage of Licensee’s non-royalty sublicense income. We are also eligible to receive tiered royalties based on a percentage of Net Sales (as defined in the A&R License Agreement) that ranges from low single digit to low teen percentages, depending on the product. Royalties are payable on a product-by-product and country-by-country basis until the latest of (i) the expiration of the last valid patent claim covering the product in the country of sale, (ii) the expiration or revocation of any applicable regulatory exclusivity in the country of sale, and (iii) ten years after the first commercial sale of the product in the country of sale. Thereafter, in consideration of licensed rights other than patent rights, royalties shall continue for the commercial life of each product but at substantially reduced rates. In addition, the royalty rates are subject to reduction by as much as 50% in a given country based on generic competition in such country. The A&R License Agreement is considered to be a contract modification in accordance with ASC Topic 606, Revenue from Contracts with Customers All revenue related to the $1.0 million upfront payment under the Original License Agreement was appropriately recognized as of the second quarter of 2019. Regulatory and commercialization milestones under the A&R License Agreement were excluded from the transaction price, as all milestone amounts were fully constrained under the guidance. Consideration related to sales-based milestones and royalties under the A&R License Agreement will be recognized when the related sales occur, provided that the reported sales are reliably measurable and that we have no remaining performance obligations, as such sales were determined to relate predominantly to the license granted to Licensee and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price in each future reporting period and as uncertain events are resolved or other changes in circumstances occur. License, Development and Commercialization Agreement with Lee’s (HK) On January 12, 2024, we entered into a License, Development and Commercialization Agreement with Lee’s (HK) effective as of January 7, 2024, or the Lee’s (HK) License Agreement. Under the Lee’s (HK) License Agreement, we granted an exclusive license, with a right to sublicense, to develop, register, make, use, sell, offer for sale, import, distribute and otherwise commercialize products that incorporate istaroxime for intravenous administration, rostafuroxin for oral administration, and our proprietary dual-mechanism SERCA2a activators for intravenous or oral administration (collectively, the Products and each, a Product), in each case for the prevention, mitigation and/or treatment of any disease, disorder or condition in humans including acute decompensated heart failure, cardiogenic shock, and chronic use following discharge of an individual hospitalized for acute decompensated heart failure, or Field, in the People’s Republic of China, Hong Kong, Macau, Taiwan, Singapore, South Korea, Thailand, Vietnam, Brunei, Myanmar, Cambodia, East Timor, Indonesia, Laos, Malaysia, and the Philippines, or the New Licensed Territory. Under the Lee’s (HK) License Agreement, we may receive up to $3.1 million in potential upfront pre-development, development, clinical, and regulatory milestone payments and up to $135.25 million in sales milestone payments. We are also entitled to receive a low double-digit percentage of Lee’s (HK) non-royalty sublicense income. We are eligible to receive tiered royalties based on a percentage of Net Sales (as defined in the Lee’s (HK) License Agreement) that ranges from low single-digit to low double-digit percentages, depending on the Product. Royalties are payable on a product-by-product and country-by-country basis until the latest of (i) the expiration of the last valid patent claim covering the Product in the country of sale, (ii) the expiration or revocation of any applicable regulatory exclusivity in the country of sale, and (iii) ten Under the Lee’s (HK) License Agreement, Lee’s (HK) will be solely and exclusively responsible for all costs and activities related to the development, manufacturing, regulatory approval and commercialization of Products in the New Licensed Territory, with the exception of certain costs in connection with filing fees payable to regulatory authorities in the New Licensed Territory relative to a Product for which we hold the applicable marketing authorization. Lee’s (HK) may sublicense its rights to its affiliates and may grant sublicenses to third-party subcontractors to perform certain activities under the Lee’s (HK) License Agreement on behalf of Lee’s (HK) or its affiliates but may not otherwise grant sublicenses to unaffiliated third parties without our prior consent. A sublicensee and a subcontractor may not be a competitor identified by us. Sublicenses granted under the Lee’s (HK) License Agreement may not include the right to further sublicense. The Lee’s (HK) License Agreement establishes a joint steering committee and a joint development committee to oversee the regional development (with us retaining final decision rights over clinical protocols) and a joint commercialization committee. During the term of the Lee’s (HK) License Agreement, we receive an exclusive (even as to Lee’s (HK)), sublicensable license under any Lee’s (HK) and its affiliate’s intellectual property that covers a Product (including its manufacture and use) and any improvements to the licensed technology developed solely by or on behalf of Lee’s (HK) or jointly with us, to (i) develop Product in the Field to obtain or maintain regulatory approval outside of the New Licensed Territory, and (ii) use, sell, offer for sale, import, export, make, have made, distribute, warehouse, market, promote, apply for and submit applications for drug approval and reimbursement approval and otherwise commercialize Product in the Field outside of the New Licensed Territory. After the term of the Lee’s (HK) License Agreement, or in the event that we wish to obtain an exclusive license under certain patent rights during or after the term, we have the option to negotiate an exclusive royalty-bearing license under any such intellectual property, provided that such royalties shall not exceed specified low single-digit caps. Under the Lee’s (HK) License Agreement, each party is responsible for prosecution and maintenance of its respective solely-owned patents, and the parties shall decide on a case-by-case basis the appropriate allocation of costs and control concerning matters regarding the prosecution, maintenance, defense and infringement of any jointly-owned patents. The Lee’s (HK) License Agreement provides for cooperation between the parties with respect to enforcement of patent rights. As between the parties, we have the first right to enforce patent rights against third parties at our own expense. If we decline to enforce such rights, Lee’s (HK) has the right to enforce such rights at its own expense. In the event that a third party claims that a Product used or sold by Lee’s (HK) (or its affiliate or sublicensee) is infringing on a patent in the New Licensed Territory, Lee’s (HK) is responsible for defending against such third party claim at its cost and expense, with the exception of certain counterclaims that we may bring. The term of the Lee’s (HK) License Agreement will continue on a country-by-country basis for the commercial life of the Products. Either party may terminate the Lee’s (HK) License Agreement in the event of bankruptcy or a material breach of the Lee’s (HK) License Agreement by the other party that remains uncured for a period of sixty days (or within 30 days after delivery of a Default Notice (as defined in the Lee’s (HK) License Agreement) if such material breach is solely based on the breaching party’s failure to pay amount due under the Lee’s (HK) License Agreement). In addition, either party may terminate the Lee’s (HK) License Agreement with respect to any individual Product in a country if a regulatory authority in such country terminates, suspends or discontinues development of such Product and such termination, suspension or discontinuance persists for a period in excess of 18 months. Upon termination of the Lee’s (HK) License Agreement in its entirety or with respect to a particular Product or country, generally all related rights and licenses granted to Lee’s (HK) will terminate, all rights under our technology will revert to us, and Lee’s (HK) will cease all use of our technology, in each case in relation to the terminated Product(s) and country(ies), as applicable. The Lee’s (HK) License Agreement constitutes a contract with a customer accounted for in accordance with ASC Topic 606. The promise of the istaroxime product, dual mechanism SERCA2a activator products, and rostafuroxin product license is the sole performance obligation provided in the Lee’s (HK) License Agreement. The performance obligation was fully satisfied as of the effective date of the Lee’s (HK) License Agreement, and no future material performance obligations are due. No revenue has been recognized under the Lee’s (HK) License Agreement. Clinical, regulatory and commercialization milestones under the Lee’s (HK) License Agreement were excluded from the transaction price, as all milestone amounts were fully constrained under the guidance. Consideration related to sales-based milestones and royalties under the Lee’s (HK) License Agreement will be recognized when the related sales occur, provided that the reported sales are reliably measurable and that we have no remaining performance obligations, as such sales were determined to relate predominantly to the license granted to Lee’s (HK) and therefore have also been excluded from the transaction price. We will re-evaluate the transaction price in each future reporting period and as uncertain events are resolved or other changes in circumstances occur.

Note 16 - Income Taxes

Note 16 - Income Taxes	9 Months Ended
Note 16 - Income Taxes	Sep. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 16 – Income Taxes During the three and nine months ended September 30, 2024, we recorded an income tax benefit of $0.2 $0.1 We have evaluated the positive and negative evidence bearing upon our ability to realize our deferred tax assets, which primarily consist of net operating losses, or NOLs. We considered the history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies, and have concluded that it is more likely than not that we will not realize the benefits of our deferred tax assets within United States jurisdiction. As such, we recorded a full valuation allowance against net deferred tax assets as of and for deferred taxes in the United States. We still have a net deferred tax liability related to our foreign operations. Utilization of NOL and R&D credit carryforwards will be subject to a substantial annual limitation under Internal Revenue Code of 1986, or IRC, Section 382, due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes will limit the amount of NOL and R&D credit carryforwards that can be utilized annually to offset future taxable income and income tax liabilities, respectively. As a result of having undergone an ownership change under IRC 382, our ability to utilize our historical NOL carryovers will be limited. We will continue to monitor any limitations on our ability to use NOLs and R&D credits in the future for all jurisdictions.

Note 17 - Subsequent Events

Note 17 - Subsequent Events	9 Months Ended
Note 17 - Subsequent Events	Sep. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	Note 17 – Subsequent Events ELOC Purchase Agreement and Redemption of Series C Preferred Stock Subsequent to September 30, 2024 and through November 21, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for gross proceeds of $3.4 million. From these proceeds we paid $0.1 million for accrued and unpaid dividends and an additional $0.9 million to redeem 794 Series C Preferred Shares as of November 21, 2024 for an aggregate redemption price of $1.0 million. Conversions of Series C Preferred Stock Subsequent to September 30, 2024 and through November 21, 2024, 3,104 shares of Series C Convertible Preferred Stock were converted into 2,322,875 shares of common stock.

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
Insider Trading Arrangements	Sep. 30, 2024	Sep. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangements During the three months ended September 30, 2024, none
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2024
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The interim unaudited condensed consolidated financial statements are prepared in accordance with US GAAP and include accounts of Windtree Therapeutics, Inc. and its wholly owned subsidiaries, CVie Investments Limited and its wholly owned subsidiary, CVie Therapeutics Limited; and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.).
Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible Assets and Goodwill We record acquired intangible assets and goodwill based on estimated fair value. The identifiable intangible assets resulting from the CVie Therapeutics acquisition in December 2018 relate to in-process research and development, or IPR&D, of istaroxime and rostafuroxin. The IPR&D assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may be impaired. During the , no events or changes in circumstances occurred indicating that our IPR&D intangible assets were more likely than not impaired. Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination and is not amortized. It is reviewed for impairment at least annually or when events or changes in the business environment indicate that its carrying value may be impaired. During each of the first and second quarters of 2023, the continued declining trend in the closing share price of our common stock suggested that the fair value of our reporting unit was more likely than not less than its carrying value. Based on interim goodwill impairment tests, we determined that the fair value of our reporting unit was more likely than not less than its carrying value. As a result, we recorded a loss on impairment of goodwill of $0.5 million in the first quarter of 2023 and an additional loss of $2.6 million, representing the remaining balance of goodwill, in the second quarter of 2023. For the nine months ended September 30, 2023, the aggregate loss on impairment of goodwill is $3.1 million, recognized within operating expenses in our condensed consolidated statements of operations. As of June 30, 2023, goodwill was written down to zero and , goodwill was zero The following table represents identifiable intangible assets as of and : September 30, December 31, (in thousands) 2024 2023 Istaroxime drug candidate $ 22,340 $ 22,340 Rostafuroxin drug candidate 2,910 2,910 Intangible assets 25,250 25,250
In Process Research and Development, Policy [Policy Text Block]	Acquired In-Process Research and Development Expenses Acquired IPR&D expenses include consideration for the purchase of IPR&D through asset acquisitions and license agreements as well as payments made in connection with asset acquisitions and license agreements upon the achievement of development milestones. We evaluate in-licensed agreements for IPR&D projects to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the in-licensed agreement for IPR&D does not meet the definition of a business and the assets have not reached technological feasibility and have no alternative future use, we expense payments made under such license agreements as research and development expense in the consolidated statements of operations. In those cases, payments for milestones achieved and payments for a product license prior to regulatory approval of the product are expensed in the period incurred. Payments made in connection with regulatory and sales-based milestones are capitalized and amortized to cost of revenue.
Derivatives, Embedded Derivatives [Policy Text Block]	Convertible Debt and Equity Instruments We review the terms of convertible debt and equity instruments to determine whether there are conversion features or embedded derivative instruments including embedded conversion options that are required to be bifurcated and accounted for separately as derivative financial instruments under ASC Topic 815, Derivatives and Hedging In circumstances where the convertible instrument contains more than one embedded derivative instrument, including conversion options that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single compound instrument. Also, in connection with the sale of convertible debt and equity instruments, we may issue free standing warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. When convertible debt or equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for separately, the total proceeds allocated to the convertible host instruments are first allocated to the fair value of the bifurcated derivative instrument. The remaining proceeds, if any, are then allocated to the convertible instruments themselves, usually resulting in those instruments being recorded at a discount from their face amount. When we issue debt securities, which bear interest at rates that are lower than market rates, we recognize a discount, which is offset against the carrying value of the debt. Such discount from the face value of the debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to income.
Derivatives, Policy [Policy Text Block]	Derivative Financial Instruments Derivatives are recorded on the consolidated balance sheet at fair value. The conversion features of the convertible notes are embedded derivatives and are separately valued and accounted for on the consolidated balance sheet with changes in fair value recognized during the period of change as a separate component of other income (expense). Fair values for exchange-traded securities and derivatives are based on quoted market prices. The pricing model we use for determining the fair value of non-exchange traded derivatives is the Monte Carlo Model. Valuations derived from this model are subject to ongoing internal and external verification and review. The model uses market-sourced inputs such as interest rates and stock price volatilities.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Transactions The functional currency for our foreign subsidiary is U.S. Dollars. We remeasure monetary assets and liabilities that are not denominated in the functional currency at exchange rates in effect at the end of each period. Gains and losses from the remeasurement of foreign currency transactions are recognized in other (expense) income, net. Foreign currency transactions resulted in a net of approximately million and a net gain of million for the three-month periods ended , respectively. Foreign currency transactions resulted in net of approximately million and million for the -month periods ended , respectively.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including intangible assets and goodwill, at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents are held at domestic and foreign financial institutions and consist of liquid investments and money market funds that are readily convertible into cash.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments, which potentially subject us to credit risk, consist principally of cash and cash equivalents. All cash and cash equivalents are held in U.S. financial institutions and money market funds. At times, we may maintain cash balances in excess of the federally insured amount of $250,000 per depositor, per insured bank, for each account ownership category. Although we currently believe that the financial institutions with whom we do business will be able to fulfill their commitments to us, there is no assurance that those institutions will be able to continue to do so. We have not experienced any credit losses associated with our balances in such accounts.
Severance Cost [Policy Text Block]	Severance In July 2023, we entered into a separation agreement with an executive, which provided that the former employee would be entitled to receive (i) a severance amount equal to the sum of the employee’s base salary then in effect and (ii) subject to certain exceptions, a pro rata bonus commensurate with the bonus awarded to other contract executives for 2023, prorated for the number of days of the employee’s employment during 2023, and payable at the time that other contract executives are paid bonuses with respect to 2023. The severance amount related to the departure of this executive was approximately $0.5 million, which was accrued in general and administrative expense at the date of the separation, and was paid ratably through July 2024. In June 2023, we implemented certain reductions in headcount. The total severance cost for impacted employees was approximately $0.2 million, which was accrued in research and development expense at the date of the separations and was paid ratably through December 2023.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three ten
Restructured Debt Liability, Contingent Milestone Payment, Policy [Policy Text Block]	Restructured Debt Liability – Contingent Milestone Payment In conjunction with the November 2017 restructuring and retirement of long-term debt, we established a $15.0 million long-term liability for contingent milestone payments potentially due under the Exchange and Termination Agreement dated as of October 27, 2017, or the Milestone Agreement, between ourselves and affiliates of Deerfield Management Company L.P., or Deerfield. The liability was recorded at the full value of the contingent milestones and was to be carried at full value until the milestones were achieved and paid or the milestones were not achieved and the liability was written off as a gain on debt extinguishment. On January 24, 2024, we and Deerfield entered into an Exchange and Termination Agreement, or the Exchange and Termination Agreement, wherein Deerfield agreed to terminate its rights to receive certain milestone payments in exchange for (i) cash in the aggregate amount of $0.2 million and (ii) an aggregate of 33,793 shares of our common stock, par value $0.001 per share (See the section titled, “Note 12 - Restructured Debt Liability”).
Research and Development Expense, Policy [Policy Text Block]	Research and Development We account for research and development expense by the following categories: (a) direct clinical and preclinical development programs, (b) product development and manufacturing, and (c) clinical, medical, and regulatory operations. Research and development expense includes personnel, facilities, manufacturing and quality, pharmaceutical development, research, clinical, regulatory, and other preclinical and clinical activities. Research and development costs are charged to operations as incurred in accordance with Accounting Standards Codification, or ASC, Topic 730, Research and Development
Income Tax, Policy [Policy Text Block]	Income Taxes We account for income taxes in accordance with ASC Topic 740, Accounting for Income Taxes We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset as there can be no assurance of realization.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Attributable to Common Stockholders Net loss is adjusted for any deemed dividends to preferred stockholders to compute net loss attributable to common stockholders. Net loss is also adjusted for any impact to retained earnings related to the extinguishment of equity securities. The Series C preferred stock and the ELOC commitment note payable are participating securities. Accordingly, in any period in which we report net income attributable to common stockholders, basic earnings per share is computed using the “two-class” method. Under this method, net income is reduced by any dividends earned and the remaining earnings (undistributed earnings) are allocated to common stock and each series of participating securities to the extent that each participating security may share in earnings as if all of the earnings for the period had been distributed. The total earnings allocated to common stock is then divided by the number of outstanding shares to which the earnings are allocated to determine the earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the participating securities have no obligation to fund losses. Diluted net income per common share is computed under the two-class method by using the weighted-average number of shares of common stock outstanding, plus the effect of any other potentially dilutive securities outstanding for the period. In addition, the Company analyzes the potential dilutive effect of the outstanding participating securities under the “if-converted” method when calculating diluted earnings per share, in which it assumes that the outstanding participating securities convert into common stock at the beginning of the period, or when issued if later. The Company reports the more dilutive of the approaches (two class or “if-converted”) as their diluted net income per share during the period. For periods in which a net loss exists, basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by giving effect to all potentially dilutive securities outstanding for the period. As of , the number of shares of common stock potentially issuable upon the exercise of certain stock options and warrants, the vesting of restricted stock units, and the conversion of Series C preferred stock and the ELOC commitment note payable was million and 0.3 million shares, respectively. For the three and nine months ended , all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted weighted-average shares of common stock outstanding. We do not have any components of other comprehensive (loss) income.

Note 4 - Summary of Significa_2

Note 4 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Intangible Assets and Goodwill [Table Text Block]	September 30, December 31, (in thousands) 2024 2023 Istaroxime drug candidate $ 22,340 $ 22,340 Rostafuroxin drug candidate 2,910 2,910 Intangible assets 25,250 25,250

Note 5 - Fair Value Measureme_2

Note 5 - Fair Value Measurements (Tables)	9 Months Ended
Note 5 - Fair Value Measurements (Tables)	Sep. 30, 2024
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Fair value measurement using September 30, (in thousands) 2024 Level 1 Level 2 Level 3 Assets: Money market funds $ 592 $ 592 $ - $ - Total Assets $ 592 $ 592 $ - $ - Liabilities: Common stock warrant liability $ (8,621 ) $ - $ - $ (8,621 ) Derivative liability - ELOC commitment note (347 ) - - (347 ) Total Liabilities $ (8,968 ) $ - $ - $ (8,968 ) Fair Value Fair value measurement using December 31, (in thousands) 2023 Level 1 Level 2 Level 3 Assets: Money market funds $ 3,532 $ 3,532 $ - $ - Total Assets $ 3,532 $ 3,532 $ - $ -
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three and Nine Months Ended September 30, 2024 Issuance of common stock warrants $ 10,787 Change in fair value (2,166 ) Balance at September 30, 2024 $ 8,621 Three and Nine Months Ended September 30, 2024 Initial recognition of derivative liability $ 286 Change in fair value 61 Balance at September 30, 2024 $ 347
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	July 22, 2024 Issuance Date July 29, 2024 Issuance Date September 30, 2024 Fair value of underlying equity $ 3.56 $ 3.29 $ 2.39 Exercise price $ 4.11 $ 4.11 $ 4.11 Volatility 108.4 % 115.6 % n/a Risk-free interest rate 4.2 % 4.1 % 3.6 Expected term (in years) 5.5 5.5 5.3 Discounting factor n/a n/a 0.83 June 26, 2024 Issuance Date September 30, 2024 Fair value of underlying equity $ 3.22 2.3442.3939 Volatility 87.3%-91.7 % 190.8%-194.4 % Risk-free interest rate 5.1 % 4.2 % Conversion price discount 20.0 % 20.0 % Discounting period (in years) 1.0 0.7 Discount rate 20.2 % 12.5 % Discounting factor 0.83 0.92

Note 14 - Stock-based Compens_2

Note 14 - Stock-based Compensation (Tables)	9 Months Ended
Note 14 - Stock-based Compensation (Tables)	Sep. 30, 2024
Notes Tables
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]	(in whole numbers) Stock Options Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (In Yrs) Outstanding at January 1, 2024 15,400 $ 1,664.00 Reverse split adjustments - fractional share round ups 106 (91.91 ) Forfeited or expired (648 ) 2,044.85 Outstanding at September 30, 2024 14,858 $ 1,551.47 8.2 Vested and exercisable at September 30, 2024 7,286 $ 3,130.51 7.4 Vested and expected to vest at September 30, 2024 14,046 $ 1,561.94 8.1
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	(in whole numbers) Restricted Stock Units Shares Weighted- Average Grant Date Fair Value Outstanding at January 1, 2024 8,180 $ 52.49 Reverse split adjustments - fractional share round ups 67 (0.42 ) Vested (140 ) 912.01 Forfeited (228 ) 21.58 Outstanding at September 30, 2024 7,879 $ 37.68
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2024 2023 2024 2023 Research and development $ 32 $ 93 $ 114 $ 280 General and administrative 55 212 321 692 Total $ 86 $ 305 $ 434 $ 972

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation (Details Textual)	Apr. 19, 2024
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	18

Note 3 - Going Concern and Ma_2

Note 3 - Going Concern and Management's Plans (Details Textual) - USD ($) $ in Thousands, shares in Millions		1 Months Ended		2 Months Ended		3 Months Ended						4 Months Ended	9 Months Ended
	Apr. 24, 2023	Oct. 31, 2024	Jul. 31, 2024	Nov. 21, 2024	Nov. 18, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Net Income (Loss) Attributable to Parent						$ (2,749)	$ (12,024)	$ 10,219	$ (4,425)	$ (6,601)	$ (4,111)		$ (4,554)	$ (15,137)
Fair Value Adjustment of Warrants						(2,166)			0				(2,166)	0
In-process Research and Development Costs													7,419	0
Gain (Loss) on Extinguishment of Debt						71			0				14,591	0
Goodwill, Impairment Loss						0			$ 0	$ 2,600	$ 500		0	3,058
Retained Earnings (Accumulated Deficit)						(848,806)						$ (848,806)	(848,806)		$ (844,823)
Proceeds from Issuance or Sale of Equity	$ 10,800
Proceeds from Issuance of Common Stock													1,367	0
Cash and Cash Equivalents, at Carrying Value						2,300						2,300	2,300		4,319
Liabilities, Current						14,426						14,426	14,426		$ 3,996
Warrants and Rights Outstanding						$ 8,600						$ 8,600	8,600
ELOC Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						1.4						1.4
Proceeds from Issuance of Common Stock, Net						$ 3,100
Proceeds from Issuance or Sale of Equity						500							4,371	$ 0
Proceeds from Issuance of Common Stock												$ 4,400
Shares Issued Value Included in Prepaid Expense						700						700	700
ELOC Purchase Agreement [Member] \| Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)				4.3	4.3
Proceeds from Issuance or Sale of Equity					$ 2,400
Proceeds from Issuance or Sale of Equity, Net		$ 3,100
Two Private Placements [Member]
Gain (Loss) on Extinguishment of Debt			$ 9,500
Proceeds from Issuance or Sale of Equity			13,900
Proceeds from Issuance of Common Stock			4,400
Proceeds from Issuance or Sale of Equity, Net			$ 2,300
June 2024 Equity Line of Credit [Member]
Agreement, Maximum Equity Value to be Issued						$ 35,000						$ 35,000	35,000
Stock Issued During Period, Shares, New Issues (in shares)						1.4
Proceeds from Issuance of Common Stock						$ 4,400
Varian Asset Acquisition [Member]
In-process Research and Development Costs													$ 7,500

Note 4 - Summary of Significa_3

Note 4 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended		3 Months Ended				9 Months Ended
	Jan. 24, 2024	Jul. 31, 2023	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Nov. 01, 2017
Goodwill, Impairment Loss				$ 0	$ 0	$ 2,600	$ 500	$ 0	$ 3,058
Goodwill			$ 0	0		$ 0		0		$ 0
Foreign Currency Transaction Gain, before Tax				100	$ 200			200	$ 300
Liability for Contingent Milestone Payment, Noncurrent				$ 0				$ 0		$ 15,000
Common Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001				$ 0.001		$ 0.001
Number of Shares of Common Stock Potentially Issuable upon the Exercise of Stock Options and Warrants (in shares)								18,900,000	300,000
Exchange and Termination Agreement with Deerfield Management Company, L.P. [Member]
Termination Agreement, Payable	$ 200
Stock Issued During Period, Shares, New Issues (in shares)	33,793
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001
Deerfield Loan [Member] \| Exchange and Termination Agreement [Member] \| Deerfield Management, L.P. [Member]
Liability for Contingent Milestone Payment, Noncurrent											$ 15,000
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)				3 years				3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)				10 years				10 years
Executive [Member]
Severance Costs		$ 500	$ 200

Note 4 - Summary of Significa_4

Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Intangible assets	$ 25,250	$ 25,250
Istaroxime Drug Candidate [Member]
Intangible assets	22,340	22,340
Rostafuroxin Drug Candidate [Member]
Intangible assets	$ 2,910	$ 2,910

Note 5 - Fair Value Measureme_3

Note 5 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Goodwill	$ 0	$ 0	$ 0

Note 5 - Fair Value Measureme_4

Note 5 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Total Assets	$ 592	$ 3,532
Total Liabilities	(8,968)
Embedded Derivative Financial Instruments, Convertible Notes [Member]
Derivative liability	(8,621)
Embedded Derivative Financial Instruments, Convertible Promissory Note [Member]
Derivative liability	(347)
Fair Value, Inputs, Level 1 [Member]
Total Assets	592	3,532
Total Liabilities	0
Fair Value, Inputs, Level 1 [Member] \| Embedded Derivative Financial Instruments, Convertible Notes [Member]
Derivative liability	0
Fair Value, Inputs, Level 1 [Member] \| Embedded Derivative Financial Instruments, Convertible Promissory Note [Member]
Derivative liability	0
Fair Value, Inputs, Level 2 [Member]
Total Assets	0	0
Total Liabilities	0
Fair Value, Inputs, Level 2 [Member] \| Embedded Derivative Financial Instruments, Convertible Notes [Member]
Derivative liability	0
Fair Value, Inputs, Level 2 [Member] \| Embedded Derivative Financial Instruments, Convertible Promissory Note [Member]
Derivative liability	0
Fair Value, Inputs, Level 3 [Member]
Total Assets	0	0
Total Liabilities	(8,968)
Fair Value, Inputs, Level 3 [Member] \| Embedded Derivative Financial Instruments, Convertible Notes [Member]
Derivative liability	(8,621)
Fair Value, Inputs, Level 3 [Member] \| Embedded Derivative Financial Instruments, Convertible Promissory Note [Member]
Derivative liability	(347)
Money Market Funds [Member]
Cash equivalents	592	3,532
Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]
Cash equivalents	592	3,532
Money Market Funds [Member] \| Fair Value, Inputs, Level 2 [Member]
Cash equivalents	0	0
Money Market Funds [Member] \| Fair Value, Inputs, Level 3 [Member]
Cash equivalents	$ 0	$ 0

Note 5 - Fair Value Measureme_5

Note 5 - Fair Value Measurements - Reconciliation of Changes in Fair Value of Liability (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Common Stock Warrant Liability [Member]
Issuance of common stock warrants	$ 10,787
Change in fair value	(2,166)
Balance at September 30, 2024	8,621
Derivative Financial Instruments, Liabilities [Member]
Issuance of common stock warrants	286
Change in fair value	61
Balance at September 30, 2024	$ 347

Note 5 - Fair Value Measureme_6

Note 5 - Fair Value Measurements - Summary of Significant Inputs in Valuation Assumption (Details)	Sep. 30, 2024	Jul. 29, 2024	Jul. 22, 2024	Jun. 26, 2024
Measurement Input, Share Price [Member]
Derivative Liability, Measurement Input				3.22
Measurement Input, Share Price [Member] \| Minimum [Member]
Derivative Liability, Measurement Input	2.34
Measurement Input, Share Price [Member] \| Maximum [Member]
Derivative Liability, Measurement Input	2.39
Measurement Input, Price Volatility [Member] \| Minimum [Member]
Derivative Liability, Measurement Input	1.908			0.873
Measurement Input, Price Volatility [Member] \| Maximum [Member]
Derivative Liability, Measurement Input	1.944			0.917
Measurement Input, Risk Free Interest Rate [Member]
Derivative Liability, Measurement Input	0.042			0.051
Measurement Input, Conversion Price [Member]
Derivative Liability, Measurement Input	0.20			0.20
Measurement Input, Discounting Period Term [Member]
Derivative Liability, Measurement Input	0.7			1
Measurement Input, Discounting Factor [Member]
Derivative Liability, Measurement Input	0.92			0.83
Measurement Input, Discount Rate [Member]
Derivative Liability, Measurement Input	0.125			0.202
Common Stock Warrant Liability [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	2.39	3.29	3.56
Common Stock Warrant Liability [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input	4.11	4.11	4.11
Common Stock Warrant Liability [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input		1.156	1.084
Common Stock Warrant Liability [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.036	0.041	0.042
Common Stock Warrant Liability [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	0.053	0.055	0.055
Common Stock Warrant Liability [Member] \| Measurement Input, Discounting Factor [Member]
Warrants and Rights Outstanding, Measurement Input	0.83

Note 6 - Senior Convertible N_2

Note 6 - Senior Convertible Notes Payable (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Apr. 02, 2024
Gain (Loss) on Extinguishment of Debt	$ 71,000	$ 0	$ 14,591,000	$ 0
Senior Convertible Notes [Member]
Convertible Debt					$ 1,350,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)					$ 6.4854
Debt Instrument, Interest Rate, Stated Percentage					10%
Debt Instrument Interest Rate Default Percentage					18%
Debt Issuance Costs, Net					$ 38,000
Debt Instrument, Unamortized Discount					$ 161,000
Debt Instrument, Interest Rate, Effective Percentage					30.32%
Interest Expense, Debt	200,000		200,000
Gain (Loss) on Extinguishment of Debt	100,000
Senior Convertible Notes [Member] \| Embedded Derivative Financial Instruments [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability	400,000		400,000		$ 500,000
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net	$ 100,000		$ 400,000
Senior Convertible Notes [Member] \| Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)					$ 1.2978

Note 7 - ELOC Commitment Note_2

Note 7 - ELOC Commitment Note Payable (Details Textual) - USD ($)	3 Months Ended	4 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Proceeds from Issuance of Common Stock			$ 1,367,000	$ 0
Series C Preferred Stock [Member]
Stock Redeemed or Called During Period, Shares (in shares)	706
ELOC Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,400,000	1,400,000
Proceeds from Issuance of Common Stock		$ 4,400,000
ELOC Purchase Agreement [Member] \| Series C Preferred Stock [Member]
Stock Redeemed or Called During Period, Shares (in shares)	705	705
Stock Redeemed or Called During Period, Value, Net	$ 1,100,000	$ 1,100,000
June 2024 Commitment Note [Member]
Debt Instrument, Face Amount	$ 350,000	$ 350,000	$ 350,000
Debt Instrument, Interest Rate, Stated Percentage	5%	5%	5%
Debt Instrument, Fair Value Disclosure	$ 600,000	$ 600,000	$ 600,000
Convertible Notes Payable, Current	$ 317,000	$ 317,000	$ 317,000		$ 0
Debt Instrument, Interest Rate, Effective Percentage	3%	3%	3%
June 2024 Commitment Note [Member] \| Embedded Derivative Financial Instruments [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability	$ 300,000	$ 300,000	$ 300,000
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net	$ 100,000		$ 100,000

Note 8 - Common Stock Warrant_2

Note 8 - Common Stock Warrant Liability (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jul. 31, 2024
Warrants and Rights Outstanding	$ 8,600,000		$ 8,600,000
Fair Value Adjustment of Warrants	$ (2,166,000)	$ 0	$ (2,166,000)	$ 0
July 2024 Warrants [Member]
Warrants and Rights Outstanding, Term (Year)					5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 4.11
Warrants and Rights Outstanding					$ 10.8

Note 9 - Senior Secured and S_2

Note 9 - Senior Secured and Senior Unsecured Notes Payable (Details Textual) - USD ($)			3 Months Ended		9 Months Ended
	Jul. 03, 2024	Jun. 28, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Gain (Loss) on Extinguishment of Debt			$ 71,000	$ 0	$ 14,591,000	$ 0
June 25, 2024 Senior Secured Notes [Member]
Debt Instrument, Face Amount		$ 300,000
June 28, 2024 Senior Secured Notes [Member]
Debt Instrument, Face Amount		100,000
June 2025 Senior Secured Notes [Member]
Proceeds from Issuance of Debt		$ 350,000
Debt Instrument, Original Issue Discount, Percentage		15%
Debt Instrument, Interest Rate, Stated Percentage		10%
Debt Instrument, Fair Value Disclosure		$ 400,000
Debt Instrument, Excess of Fair Value Over Face Value		$ 41,000
July 2024 Senior Secured Notes [Member]
Debt Instrument, Face Amount	$ 100,000
July 2024 Senior Unsecured Promissory Note [Member]
Debt Instrument, Face Amount	100,000
July 2024 Notes [Member]
Proceeds from Issuance of Debt	$ 200,000
Debt Instrument, Original Issue Discount, Percentage	15%
Debt Instrument, Interest Rate, Stated Percentage	10%
Debt Instrument Interest Rate Default Percentage	18%
Debt Instrument, Fair Value Disclosure	$ 230,000
Debt Instrument, Excess of Fair Value Over Face Value	$ 27,000
June 2025 Senior Secured Notes and July 2024 Notes [Member]
Debt Instrument, Fair Value Disclosure			700,000		700,000
Gain (Loss) on Extinguishment of Debt			0
Long-Term Debt, Gross			$ 0		$ 0

Note 10 - Loans Payable (Detail

Note 10 - Loans Payable (Details Textual) - Loans Payable With IPFS Corporation [Member] - USD ($)	10 Months Ended
	May 31, 2025	Apr. 30, 2024	Sep. 30, 2024	Aug. 31, 2024	Dec. 31, 2023
Debt Instrument, Face Amount				$ 500,000	$ 800,000
Debt Instrument, Interest Rate, Stated Percentage				7.94%	7.24%
Debt Instrument, Periodic Payment		$ 77,000
Loans Payable to Bank			$ 400,000		$ 200,000
Forecast [Member]
Debt Instrument, Periodic Payment	$ 56,000

Note 11 - Other Current Liabi_2

Note 11 - Other Current Liabilities (Details Textual) - USD ($)

1 Months Ended

Jan. 01, 2025

Nov. 25, 2024

Nov. 16, 2024

Nov. 15, 2024

Oct. 29, 2024

Sep. 30, 2024

Sep. 15, 2024

Aug. 02, 2024

Jul. 17, 2024

Jul. 02, 2024

Jul. 01, 2024

Jan. 19, 2024

Jan. 18, 2024

Oct. 31, 2024

Jan. 17, 2024

Dec. 31, 2023

License Agreement with Philip Morris USA for Aerosolization Technology [Member]

License Agreement, Fee

$ 400,000

$ 100,000

License Agreement, Maximum Milestone Payments

$ 1,400,000

License Agreement, Annual Interest on Deferred Payment, Percentage

18%

Licensing Agreement Accrued Payments

$ 500,000

$ 900,000

License Agreement with Philip Morris USA for Aerosolization Technology [Member] | Forecast [Member]

License Agreement, Increased Annual Interest on Deferred Payment, Percentage

36%

License Agreement with Philip Morris USA for Aerosolization Technology [Member] | Subsequent Event [Member]

License Agreement, Fee

$ 200,000

License Agreement, Increased Annual Interest on Deferred Payment, Percentage

27%

Licensing Agreement Accrued Payments

$ 200,000

Payments for Licensing Fees

$ 200,000

License Agreement with Philip Morris Products for Aerosolization Technology [Member]

License Agreement, Fee

$ 200,000

$ 325,000

$ 75,000

License Agreement, Maximum Milestone Payments

$ 1,400,000

License Agreement, Annual Interest on Deferred Payment, Percentage

18%

License Agreement with Philip Morris Products for Aerosolization Technology [Member] | Subsequent Event [Member]

License Agreement, Fee

$ 125,000

License Agreement, Increased Annual Interest on Deferred Payment, Percentage

27%

Licensing Agreement Accrued Payments

$ 125,000

Note 12 - Restructured Debt L_2

Note 12 - Restructured Debt Liability (Details Textual) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended				9 Months Ended
	Jan. 24, 2025	Jan. 24, 2024	Oct. 27, 2017	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Liability for Contingent Milestone Payment, Noncurrent				$ 0				$ 0		$ 15,000
Common Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001				$ 0.001		$ 0.001
Gain (Loss) on Extinguishment of Debt				$ 71		$ 0		$ 14,591	$ 0
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)				0	0		236,000
Exchange and Termination Agreement with Deerfield Management Company, L.P. [Member]
Termination Agreement, Payable		$ 200
Payments for Exchange and Termination Agreement		$ 100
Stock Issued During Period, Shares, New Issues (in shares)		33,793
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.001
Exchange and Termination Agreement with Deerfield Management Company, L.P. [Member] \| Forecast [Member]
Payments for Exchange and Termination Agreement	$ 100
Deerfield Loan [Member] \| Exchange and Termination Agreement [Member] \| Deerfield Management, L.P. [Member]
Extinguishment of Debt, Amount			$ 25,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			10
Class of Warrant or Right, Exercise Price of Cancelled Warrants (in dollars per share)			$ 2,124,360
Repayments of Long-term Debt, Total			$ 2,500
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations (in shares)			27
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations, Percentage of Fully-diluted Shares Outstanding			2%
Liability for Contingent Milestone Payment, Noncurrent			$ 15,000							$ 15,000	$ 15,000
Gain (Loss) on Extinguishment of Debt								14,500
Deerfield Loan [Member] \| Exchange and Termination Agreement [Member] \| Deerfield Management, L.P. [Member] \| Common Stock [Member]
Liability for Contingent Milestone Payment, Noncurrent				$ 300				300
Deerfield Loan [Member] \| Exchange and Termination Agreement [Member] \| Deerfield Management, L.P. [Member] \| Cash [Member]
Liability for Contingent Milestone Payment, Noncurrent				$ 200				$ 200

Note 13 - Mezzanine Equity an_2

Note 13 - Mezzanine Equity and Stockholders' Equity (Details Textual) - USD ($)										1 Months Ended	2 Months Ended		3 Months Ended						4 Months Ended	9 Months Ended
	Jul. 26, 2024	Jul. 19, 2024	Jul. 18, 2024	Apr. 03, 2024	Apr. 02, 2024	Nov. 09, 2023	Apr. 24, 2023	Feb. 21, 2023	Jan. 20, 2023	Oct. 31, 2024	Nov. 21, 2024	Nov. 18, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Jul. 31, 2024	Dec. 31, 2023
Preferred Stock, Par or Stated Value Per Share (in dollars per share)													$ 0.001						$ 0.001	$ 0.001			$ 0.001
Proceeds from Issuance of Private Placement																				$ 3,925,000	$ 0
Proceeds from Issuance or Sale of Equity							$ 10,800,000
Warrants and Rights Outstanding													$ 8,600,000						$ 8,600,000	8,600,000
Stock Issued During Period, Value, New Issues													0	$ 0			$ 10,794,000
Conversion of Stock, Amount Converted													209,000
Gain (Loss) on Extinguishment of Debt													71,000			$ 0				14,591,000	0
Stock Issued During Period, Value, Conversion of Convertible Securities													0		$ 280,000
Preferred Stock, Value, Issued													$ 0						$ 0	$ 0			$ 0
Common Stock, Par or Stated Value Per Share (in dollars per share)													$ 0.001						$ 0.001	$ 0.001			$ 0.001
Stock Redeemed or Called During Period, Value													$ 772,000
Preferred Stock, Redemption Premium, Percentage													20%						20%	20%
Dividends, Preferred Stock, Cash													$ 347,000
Proceeds from Issuance of Common Stock																				$ 1,367,000	0
Preferred Stock, Shares Outstanding (in shares)													0						0	0			0
Equity Issued During Period, Units, New Issues (in shares)							204,779
Units, Number of Warrants Called by Each Unit (in shares)							1
Shares Issued, Price Per Share (in dollars per share)							$ 52.74
Proceeds from Issuance or Sale of Equity, Gross							$ 12,400,000
Stock Issued During Period, Value, Exercise Of Warrants																		$ 843,000
Proceeds from Warrant Exercises																				$ 0	843,000
Asset Purchase Agreement With Varian Biopharmaceuticals, Inc. [Member]
Asset Purchase Agreement, Contingent Consideration					$ 2,300,000
ELOC Purchase Agreement [Member]
Agreement, Maximum Equity Value to be Issued														$ 35
June 2024 Equity Line of Credit [Member]
Stock Issued During Period, Shares, New Issues (in shares)													1,400,000
Agreement, Maximum Equity Value to be Issued													$ 35,000,000						$ 35,000,000	35,000,000
Proceeds from Issuance of Common Stock													4,400,000
Proceeds From Equity Issuance Receivable													700,000						700,000	700,000
Senior Convertible Notes With First PIPE [Member]
Long-Term Debt, Gross																						$ 1,200,000
Gain (Loss) on Extinguishment of Debt													46,000
Senior Convertible Notes With First PIPE [Member] \| Embedded Derivative Financial Instruments [Member]
Derivative Liability													300,000						300,000	300,000
June and July Notes [Member]
Gain (Loss) on Extinguishment of Debt													0
June 2024 Commitment Note [Member]
Debt Instrument, Fair Value Disclosure													$ 600,000						600,000	600,000
Conversion of Series C Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)													313,071
Conversion of Stock, Amount Converted													$ 55,000
Conversion of Stock, Shares Converted (in shares)													1,116
Gain (Loss) on Conversion of Stock													$ 0
Conversion of Series C Preferred Stock Into Common Stock [Member] \| Subsequent Event [Member]
Conversion of Stock, Shares Issued (in shares)											2,322,875
Conversion of Stock, Shares Converted (in shares)											3,104
July 2024 First Purchase Agreement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			3,440,631
Class of Warrant or Right, Issued During Period (in shares)													909,094
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 4.11
Warrants and Rights Outstanding													$ 2,600,000						2,600,000	2,600,000
July 2024 First Purchase Agreement Warrants [Member] \| First Private Placement to Senior Convertible Notes [Member]
Class of Warrant or Right, Exchanged During Period													444,536						444,536	444,536
July 2024 First Purchase Agreement Warrants [Member] \| First Private Placement to June and July Notes [Member]
Class of Warrant or Right, Exchanged During Period													206,277						206,277	206,277
July 2024 First Purchase Agreement Warrants [Member] \| First Private Placement to Series B [Member]
Class of Warrant or Right, Exchanged During Period													$ 1,880,724						1,880,724	1,880,724
July 2024 First Purchase Agreement Warrants [Member] \| Chief Executive Officer [Member]
Class of Warrant or Right, Issued During Period (in shares)			4,011
July 2024 First Purchase Agreement Warrants [Member] \| Chief Managerial Officer [Member]
Class of Warrant or Right, Issued During Period (in shares)			2,674
July 2024 Second Purchase Agreement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	267,380
Class of Warrant or Right, Issued During Period (in shares)													267,380
Warrants and Rights Outstanding													$ 726,000						$ 726,000	726,000
July 2024 Second Purchase Agreement Warrants [Member] \| Placement Agent Fees and Expenses [Member]
Class of Warrant or Right, Issued During Period (in shares)	8,022
July 2024 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																						$ 4.11
Warrants and Rights Outstanding																						$ 10.8
Warrants and Rights Outstanding, Term (Year)																						5 years
April 2023 Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 52.74
Warrants and Rights Outstanding, Term (Year)							5 years
December 2019 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								307	88
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 10,881	$ 10,881
May 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								307	311
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 7,177.5	$ 7,177.5
March 2021 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									4,945
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)									$ 3,240
January 2023 Existing Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									5,343
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)									$ 180
Stock Issued During Period, Value, Exercise Of Warrants									$ 1,000,000
Proceeds from Warrant Exercises								$ 700,000	$ 700,000
Fair Value of Warrant Modifications Related to Warrant Exercise Inducement								$ 1,200,000												0	1,238,000
January 2023 New Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									10,686
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)									$ 193.68
Warrants and Rights Outstanding, Term (Year)									5 years
July 2018 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								70
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 10,800
December 2018 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								554
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 10,935
February 2023 Existing Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								1,236
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 127.08
Stock Issued During Period, Value, Exercise Of Warrants								$ 200,000
Proceeds from Warrant Exercises								100,000
Fair Value of Warrant Modifications Related to Warrant Exercise Inducement								$ 300,000												0	274,000
February 2023 New Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								2,472
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 193.68
Warrants and Rights Outstanding, Term (Year)								5 years
July 2024 First Purchase Agreement [Member]
Proceeds from Issuance of Private Placement			$ 12,900,000
Noncash Proceeds from Issuance of Private Placement			9,500,000
Proceeds from Issuance or Sale of Equity													3,100,000
Lead Buyer Reimbursements													0.3
July 2024 First Purchase Agreement [Member] \| First Private Placement to June and July Notes [Member]
Conversion of Stock, Amount Converted													700,000
July 2024 First Purchase Agreement [Member] \| First Private Placement to Series B [Member]
Conversion of Stock, Amount Converted													6,400,000
First PIPE [Member] \| Chief Executive Officer [Member]
Proceeds from Issuance or Sale of Equity			15,000
First PIPE [Member] \| Chief Managerial Officer [Member]
Proceeds from Issuance or Sale of Equity			$ 10,000
July 2024 Second Purchase Agreement [Member]
Proceeds from Issuance of Private Placement	$ 1,000,000
Proceeds from Issuance or Sale of Equity													975,000
Lead Buyer Reimbursements													25,000
First and Second Private Placement [Member]
Payments of Stock Issuance Costs													800,000
First and Second Private Placement [Member] \| July 2024 First Purchase Agreement Placement Agent [Member]
Payments of Stock Issuance Costs													200,000
First and Second Private Placement [Member] \| July 2024 Warrants [Member]
Payments of Stock Issuance Costs													$ 900,000
ELOC Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)													1,400,000						1,400,000
Proceeds from Issuance or Sale of Equity													$ 500,000							$ 4,371,000	0
Stock Issued During Period, Value, New Issues													$ 4,371,000
Proceeds from Issuance of Common Stock																			$ 4,400,000
Stock Issued During Period, Value, New Issues, Percentage of Total Proceeds													30%
ELOC Purchase Agreement [Member] \| Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)											4,300,000	4,300,000
Proceeds from Issuance or Sale of Equity												$ 2,400,000
Stock Redeemed or Called During Period, Shares (in shares)											794
Stock Redeemed or Called During Period, Value											$ 900,000
Stock Redeemed or Called During Period, Value, Net											1,000,000
Proceeds from Issuance or Sale of Equity, Net										$ 3,100,000
Proceeds from Issuance or Sale of Equity, Gross											$ 3,400,000
Over-Allotment Option [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							30,717
Overallotment, Potential Issuable Shares (in shares)							30,717
ATM Program [Member]
Stock Issued During Period, Shares, New Issues (in shares)																				143,120
Stock Issued During Period, Value, New Issues															$ 1,367,000
Proceeds from Issuance of Common Stock																				$ 1,400,000
ATM Program [Member] \| Ladenburg [Member]
Commission Fee, Percent Fee						3%
Reimbursement, Maximum Disbursement						$ 60,000
Reimbursement, Additional Maximum Quarterly Disbursement						$ 3,000
Series C Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 1,000											$ 1,000						$ 1,000	$ 1,000
Stock Issuance Agreement, Shares Authorized (in shares)		18,820
Preferred Stock, Convertible, Conversion Price (in dollars per share)		$ 3.74
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)		267
Preferred Stock, Dividend Rate, Percentage		10%
Preferred Stock Dividend Rate Triggering Event Percentage		18%
Stock Redeemed or Called During Period, Shares (in shares)													706
Series C Preferred Stock [Member] \| Reclassified to Common Stock [Member]
Preferred Stock, Value, Issued													$ 154,000						$ 154,000	$ 154,000
Series C Preferred Stock [Member] \| Minimum [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)		$ 1.28
Series C Preferred Stock [Member] \| July 2024 First Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			16,099										4,255
Preferred Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.001
Stock Issued During Period, Value, New Issues													$ 500,000
Series C Preferred Stock [Member] \| July 2024 First Purchase Agreement [Member] \| First Private Placement to Senior Convertible Notes [Member]
Conversion of Stock, Shares Issued (in shares)													2,080
Conversion of Stock, Amount Converted													$ 1,500,000
Series C Preferred Stock [Member] \| July 2024 First Purchase Agreement [Member] \| First Private Placement to June and July Notes [Member]
Conversion of Stock, Shares Issued (in shares)													966
Series C Preferred Stock [Member] \| July 2024 First Purchase Agreement [Member] \| First Private Placement to Series B [Member]
Conversion of Stock, Shares Issued (in shares)													8,798
Series C Preferred Stock [Member] \| July 2024 First Purchase Agreement [Member] \| July 2024 First Purchase Agreement Placement Agent [Member]
Stock Issued During Period, Shares, New Issues (in shares)			161
Class of Warrant or Right, Issued During Period (in shares)			62,892
Series C Preferred Stock [Member] \| First PIPE [Member] \| Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues (in shares)			19
Series C Preferred Stock [Member] \| First PIPE [Member] \| Chief Managerial Officer [Member]
Stock Issued During Period, Shares, New Issues (in shares)			13
Series C Preferred Stock [Member] \| July 2024 Second Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,250												1,250
Stock Issued During Period, Value, New Issues													$ 249,000
Series C Preferred Stock [Member] \| July 2024 Second Purchase Agreement [Member] \| Placement Agent Fees and Expenses [Member]
Stock Issued During Period, Shares, New Issues (in shares)	30
Series C Preferred Stock [Member] \| First and Second Private Placement [Member]
Payments of Stock Issuance Costs													$ 1,100,000
Series C Preferred Stock [Member] \| First and Second Private Placement [Member] \| July 2024 First Purchase Agreement Placement Agent [Member]
Class of Warrant or Right, Issued During Period (in shares)													70,914
Series C Preferred Stock [Member] \| First and Second Private Placement [Member] \| First and Second Purchase Agreement Placement Agent [Member]
Stock Issued During Period, Shares, New Issues (in shares)													191
Series C Preferred Stock [Member] \| ELOC Purchase Agreement [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)													$ 1,000						$ 1,000	$ 1,000
Stock Redeemed or Called During Period, Shares (in shares)													705						705
Stock Redeemed or Called During Period, Value													$ 800,000
Preferred Stock, Redemption Premium, Percentage													20%						20%	20%
Dividends, Preferred Stock, Cash													$ 300,000
Stock Redeemed or Called During Period, Value, Net													$ 1,100,000						$ 1,100,000
Series C Preferred Stock [Member] \| ELOC Purchase Agreement [Member] \| Subsequent Event [Member]
Stock Redeemed or Called During Period, Shares (in shares)										133
Stock Redeemed or Called During Period, Value										$ 150,000
Dividends, Preferred Stock, Cash										50,000
Stock Redeemed or Called During Period, Value, Net										$ 200,000
Series B Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)					5,500
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 1,000	$ 0.001
Stock Issuance Agreement, Shares Authorized (in shares)				5,500
Preferred Stock, Convertible, Conversion Price (in dollars per share)				$ 6.4854
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				155
Preferred Stock, Dividend Rate, Percentage				10%
Stock Issued During Period, Value, New Issues					$ 7,000,000
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)													5,500
Stock Issued During Period, Value, Conversion of Convertible Securities													$ 7,000,000
Payments of Stock Issuance Costs				$ 68,000																$ 68,000	$ 0
Preferred Stock, Value, Issued				7,000,000
Stock Issuance Agreement, Amount Authorized				$ 5,500,000
Preferred Stock, Shares Outstanding (in shares)													0						0	0
Series B Preferred Stock [Member] \| Minimum [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)				$ 1.2978
Series B Preferred Stock [Member] \| July 2024 First Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			5,500

Note 14 - Stock-based Compens_3

Note 14 - Stock-based Compensation (Details Textual)	9 Months Ended
Note 14 - Stock-based Compensation (Details Textual)	Sep. 30, 2024
Share-Based Payment Arrangement, Option [Member] \| Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
Restricted Stock Units (RSUs) [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period (Year)	1 year
Restricted Stock Units (RSUs) [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period (Year)	3 years

Note 14 - Stock-based Compens_4

Note 14 - Stock-based Compensation - Summary Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Shares Outstanding, Beginning Balance (in shares) \| shares	15,400
Weighted Average Exercise Price, Outstanding, at Beginning Period (in dollars per share) \| $ / shares	$ 1,664
Reverse split adjustments - fractional share round ups (in shares) \| shares	106
Weighted Average Exercise Price, Reverse split adjustments - fractional share round ups (in dollars per share) \| $ / shares	$ (91.91)
Shares Forfeited or Expired (in shares) \| shares	(648)
Weighted Average Exercise Price, Forfeited or Expired (in dollars per share) \| $ / shares	$ 2,044.85
Shares Outstanding, Ending Balance (in shares) \| shares	14,858
Weighted Average Exercise Price, Outstanding, at Ending Period (in dollars per share) \| $ / shares	$ 1,551.47
Weighted Average Remaining Contractual Life, Outstanding (Year)	8 years 2 months 12 days
Shares Vested and Exercisable (in shares) \| shares	7,286
Weighted Average Exercise Price, Vested and Exercisable (in dollars per share) \| $ / shares	$ 3,130.51
Weighted Average Remaining Contractual Life, Vested and Exercisable (Year)	7 years 4 months 24 days
Vested and expected to vest (in shares) \| shares	14,046
Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share) \| $ / shares	$ 1,561.94
Weighted Average Remaining Contractual Life, Vested and Expected to Vest (Year)	8 years 1 month 6 days

Note 14 - Stock-based Compens_5

Note 14 - Stock-based Compensation - Restricted Stock Units (Details)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Reverse split adjustments - fractional share round ups (in shares)	106
Restricted Stock Units (RSUs) [Member]
Balance (in shares)	8,180
Weighted- Average Grant Date Fair Value, Outstanding, Beginning Balance (in dollars per share) \| $ / shares	$ 52.49
Reverse split adjustments - fractional share round ups (in shares)	67
Weighted- Average Grant Date Fair Value, Reverse split adjustments - fractional share round ups (in dollars per share) \| $ / shares	$ (0.42)
Vested (in shares)	(140)
Vested Weighted- Average Grant Date Fair Value, Outstanding (in dollars per share) \| $ / shares	$ 912.01
Forfeited (in shares)	(228)
Forfeited Weighted- Average Grant Date Fair Value, Outstanding (in dollars per share) \| $ / shares	$ 21.58
Outstanding at September 30, 2024 (in shares)	7,879
Outstanding at September 30, 2024 (in dollars per share) \| $ / shares	$ 37.68

Note 14 - Stock-based Compens_6

Note 14 - Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Stock-based compensation expense	$ 86	$ 305	$ 434	$ 972
Research and Development Expense [Member]
Stock-based compensation expense	32	93	114	280
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 55	$ 212	$ 321	$ 692

Note 15 - Licensing and Resea_2

Note 15 - Licensing and Research Funding Agreements (Details Textual) - USD ($) $ in Thousands

3 Months Ended

12 Months Ended

May 09, 2024

Apr. 02, 2024

Jan. 12, 2024

Sep. 30, 2024

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2019

Dec. 31, 2021

Dec. 31, 2022

Aug. 17, 2022

Sep. 30, 2020

Mar. 18, 2020

Stock Issued During Period, Value, New Issues

$ 0

$ 10,794

Term Sheet With Lee [Member]

Proceeds for Payments to Develop Product

$ 1,000

Financing of Product, Percent of Financing That Must be Repaid to Discontinue Revenue Sharing

125%

Financing of Product, Percent of Revenue Shared With Financer

50%

Term Sheet With Lee [Member] | Other Liabilities [Member]

Contractual Obligation, Total

$ 3,800

A&R License Agreement With Lee [Member]

Proceeds for Payments to Develop Product

$ 1,000

Maximum Amount May be Received for Potential Milestone Payments

$ 78,900

License Agreement with Lee’s Pharmaceutical (HK) Ltd. [Member]

Maximum Amount May be Received for Potential Milestone Payments

$ 3,100

Maximum Amount May be Received for Sales Milestone Payments

$ 135,250

Royalties to be Received, Period After First Commercial Sale (Year)

10 years

Royalty Rate Reduction Percentage

50%

Momentum Research Inc. [Member]

Payments For Performance of Collaborative Agreement

$ 1,200

Accounts Payable, Interest-Bearing, Interest Rate

18%

Momentum Research Inc. [Member] | Istaroxine Revenue [Member]

Percentage of Revenue, Pay to Counter Party

Lee’s Pharmaceutical Holdings Limited [Member] | AEROSURF Funding Term Sheet [Member]

Nonrefundable Payments, Maximum Financing to Be Received Under Special Circumstances

$ 2,800

Asset Purchase Agreement With Varian Biopharmaceuticals, Inc. [Member]

Asset Purchase Agreement, Contingent Consideration

$ 2,300

Series B Preferred Stock [Member]

Stock Issued During Period, Shares, New Issues (in shares)

5,500

Stock Issued During Period, Value, New Issues

$ 7,000

Note 16 - Income Taxes (Details

Note 16 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Expense (Benefit)	$ (240)	$ 0	$ 71	$ 0

Note 17 - Subsequent Events (De

Note 17 - Subsequent Events (Details Textual) - USD ($) $ in Thousands		2 Months Ended		3 Months Ended	4 Months Ended	9 Months Ended
	Apr. 24, 2023	Nov. 21, 2024	Nov. 18, 2024	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
Proceeds from Issuance or Sale of Equity, Gross	$ 12,400
Payments of Dividends						$ 347	$ 0
Stock Redeemed or Called During Period, Value				$ 772
Conversion of Series C Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)				1,116
Conversion of Stock, Shares Issued (in shares)				313,071
Subsequent Event [Member] \| Conversion of Series C Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)		3,104
Conversion of Stock, Shares Issued (in shares)		2,322,875
ELOC Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)				1,400,000	1,400,000
ELOC Purchase Agreement [Member] \| Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)		4,300,000	4,300,000
Proceeds from Issuance or Sale of Equity, Gross		$ 3,400
Payments of Dividends		100
Stock Redeemed or Called During Period, Value		$ 900
Stock Redeemed or Called During Period, Shares (in shares)		794
Stock Redeemed or Called During Period, Value, Net		$ 1,000